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Abstract 
Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis and 
represents the most common seronegative spondyloarthropathy with an approximate 
prevalence of one in one thousand Caucasians. Clinically, AS commonly presents as a 
predominantly axial arthritis affecting the spine and girdle joints. AS is a complex genetic 
disease with multiple susceptibility factors. Though it is known AS susceptibility has a 
strong genetic component, with a sibling recurrence risk (A.s) of82, the majority of the 
susceptibility genes are unidentified. 
Objective: The objective of this study was to identify and test potential candidate genes 
for susceptibility to AS in the Newfoundland population. Candidate genes were chosen 
based on functional relevance to disease phenotype or on positional proximity to known 
chromosome regions of linkage to AS. 
Methods: All patients with AS met the modified New York Criteria and the controls were 
ethnically matched. A Newfoundland cohort of 101 AS patients and 103 ethnically 
matched controls were genotyped using the Sequenom MassArray platform. All controls 
met Hardy Weinberg equilibrium. Analysis was performed using appropriate statistical 
tests. 
Results: The minor allele frequencies for the candidate genes TLR4 Asp299Gly 
CPc=0.05) and TNFa promoter polymorphisms -308 CPc=0.008), -863/-1031 (in linkage 
disequilibrium Pc=O.OOO) were found to be associated with AS. Other candidate genes 
tested showed no association with disease. Minor alleles of the single nucleotide 
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polymorphisms chosen for the candidate genes FGFR2, TCIRG 1, and DLL3 were not 
present in the Newfoundland population. No secondary associations of phenotype and 
genotype were noted for disease severity indices, gender or age of onset. 
Conclusion: A novel association was noted between TLR4 and AS and the association of 
promoter polymorphisms ofTNFa was validated in the Newfoundland population. 
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Chapter 1: Introduction 
1.1 THE PHENOTYPE 
1.1.1 Epidemiology 
Ankylosing spondylitis (AS) has been present in society since ancient times. 
Recent studies ofX-rays taken ofthe mummies of Amenhotep II (Greek name 
Amenophis), Ramses II (Ramses the Great), and Merenptah (son ofRamses II and next 
Pharaoh of Egypt) show all three had ossification of the spine as is seen in AS 
(Feldtkeller et al., 2003). 
AS is a chronic inflammatory arthritis (Laval et al., 2001), and represents the most 
common seronegative spondyloarthropathy with an approximate prevalence of one out of 
one thousand Caucasians (Brown et al., 2003). This prevalence may be underestimated as 
patients with mild disease are commonly overlooked. Clinically, AS commonly presents 
as a predominantly axial arthritis affecting the spine and girdle joints. Enthesitis, the 
inflammation of tendon where it inserts into bone, is a common presenting feature of AS. 
Peripheral arthritis of distal joints can also occur, but is less common. Extra-articular 
features include inflammatory bowel disease (IBD) and acute anterior uveitis, also known 
as iritis. 
There are gender differences in AS. It has been reported that the prevalence of the 
disease is primarily in males with a three to one ratio of male to female AS patients 
(Brophy et al., 2003). There are differences in presentation of the disease for each gender 
(Mori et al., 2003). Clinically, male patients tend to have primarily axial involvement, 
while females are more likely to also have peripheral arthritis symptoms (Mori et al., 
2003). Men are generally more likely to have a younger age of onset and a higher 
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frequency of extra-articular features such as psoriasis and inflammatory bowel disease 
than women (Breban et al., 2003). 
1.1.2 Clinical Features 
Spondyloartbropathy 
AS is a disease that presents primarily with axial symptoms. Lower back pain is 
the first symptom in three quarters of AS patients. A distinguishing characteristic of the 
inflammatory back pain felt with AS over mechanical back pain is the pain tends to 
improve with exercise and worsen with rest. Suspicion of AS is indicated when the onset 
is insidious, onset occurs when patient is under the age of 40, and the duration of pain is 
over three months. In the spinal column, the disease process is one of inflammation at 
areas of contact between ligament and vertebrae. In areas of enthesitis, surgical samples 
show edema and inflammation, extending into adjacent bone marrow (Laloux eta/., 
2001 ). Cytotoxic CD8+ T cells and macrophages are plentiful, with fewer CD4+ helper T 
lymphocytes in these areas (McGonagle eta/., 2002). Biopsies of the sacroiliac joint 
show areas of new cartilage formation, osteitis, and subchondral granulation tissue, as 
well as evidence ofboth synovitis and enthesitis (Francois eta/., 2000). 
Peripheral Jojnts 
Synovial joints are also involved in AS, most commonly in the hip and shoulder 
joints. Histological examination of samples from AS hip joints reveal fibrin, proliferation 
of lining cells, inflammatory infiltrate with lymphocytes and large numbers of plasma 
cells (Chang eta/., 1992). Manifestation of synovitis may be by erythema, swelling, and 
tenderness. These signs are more readily apparent in superficial joints, and may not be 
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seen at all in deep joints such as the hip and shoulder, where pain and limited range of 
motion may be the only symptoms. 
Extra-articular Manifestations 
The eyes, lungs, gastrointestinal tract, and heart can be affected in AS. As well, 
AS patients can have non-specific systemic signs of inflammation such as mild fever, 
fatigue and weight loss. Iritis, inflammation of the uveal tract, is the most common 
extraarticular complication in AS, occurring in twenty five to forty percent of patients 
(Maksymowych eta/., 1995). There is some evidence that AS patients with more 
peripheral involvement are more likely to develop iritis (Maksymowych et a/., 1995). 
Iritis typically presents as acute unilateral eye pain, sensitivity to light and blurring of 
vision. Acute episodes may last two to three months, but rarely lead to permanent 
impairment of vision. 
While the presence of diagnosed IBD in AS patients is one to four percent, 
subclinical inflammation of the gut and bowel is seen in forty to sixty percent of AS 
patients (Baeten et al., 2002). An estimated ten to fifteen percent of IBD patients have 
disease complicated by AS (Crane et al., 2002). The diseases seem to be linked 
epidemiologically through a common aberration of the immune system as both respond to 
similar therapies, such as the anti-TNFa biologic treatment (as reviewed in Vermiere et 
al., 2002). 
Prognosis 
Most patients with mild disease and minimal peripheral involvement will be able 
to maintain most of their joint range of motion, and functional capacity. Disease activity 
usually varies within the individual patient with "flares" of worsening disease activity. 
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Symptoms usually persist throughout life, though a small minority will enter a stage of 
disease "burnout" where the disease does not progress any further (Kennedy eta!., 1993). 
Prognostic indicators of worse disease activity include hip arthritis, dactylitis, poor 
efficacy of non-steroidal anti-inflammatory drugs (NSAID), high erythrocyte 
sedimentation rate (ESR) (>30), limitation in range of motion in the lumbar spine, 
oligoarthritis, and age of onset under 16 (Amoret a!., 1994). Smoking has been linked to 
poorer outcomes. AS does not negatively affect mortality. While quality of life is 
significantly decreased, lifespan is normal in severe as well as mild cases. The burden of 
illness in AS is high and may be comparable to that of rheumatoid arthritis (Zink et a!., 
2000). Pain from spine inflammation is significant and persistent (Scalapino and Davis, 
2003). There is impact on employability and quality of life throughout the disease course. 
1.1.3 Laboratory Studies 
Laboratory studies in AS are non-specific and non-diagnostic. ESR is frequently 
elevated, as are levels of C reactive protein (CRP). Mild anemia may also be seen. 
Serology for rheumatoid factor is typically negative. Levels of complement may be 
slightly elevated reflecting an acute inflammatory state. Testing for HLA-B27 has 
negative predictive value only, as a patient that is HLA-B27 negative is unlikely to have 
AS unless the clinical symptoms are diagnostic. However, the prevalence ofHLA-B27 in 
the population without AS is high enough that the presence of the allele alone is not 
diagnostic for the disease, so the positive predictive value is poor. 
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1.1.4 X-Ray Findings 
Radiography of the sacroiliac joints is necessary for the definitive diagnosis of 
AS. Radiographic grading of the changes to the sacroiliac joint progresses through 
normal, sclerosis with some erosions, severe erosions with widening of joint space, and 
finally complete ankylosis, or fusion of the joint. To best view the joint, the Ferguson 
view is commonly used. In this method the patient lies prone and the X-ray is angled 
thirty degrees towards the patient's head. It is important to recognize that early changes 
to the sacroiliac joint that occur in the first stages of the disease are not apparent on plain 
film. As radiographic changes are necessary to diagnose AS, if symptoms continue, 
repeated X-rays are warranted. 
Other changes that can be seen on plain X-ray are changes associated with 
enthesitis. Erosions or osteitis of the ischial tuberosities, the iliac crest, or the femoral 
trochanter can be used to determine extent of peripheral involvement. Squaring of the 
vertebral bodies is an early change that allows suspicion of an AS diagnosis. 
Magnetic Resonance Imaging is a better tool for early diagnosis of AS. Early 
bony changes detected by MRI progress to the radiographic changes diagnostic of AS on 
later X-ray. While in early cases this is the imaging method of choice, in most centres 
access to the MRI machine is limited for AS. 
Studies are currently underway to determine the efficacy of ultrasound in early 
diagnosis of AS. To date, this method is infrequently used due to the large variability 
seen with operator expertise and the imaging itself takes a substantial amount oftime 
with both an affected and unaffected joint for comparison. Bone density scans can be 
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used to assess osteoporosis levels in the spine and predict patients more likely to undergo 
vertebral fracture. 
1.1.5 Diagnostic Criteria 
Diagnosis is performed using the standardized modified New York criteria. To be 
diagnosed with AS by these criteria, patients must have radiological evidence of 
sacroiliitis (at least grade II bilaterally or grade III-IV unilaterally), and must have at least 
one of the following clinical criteria: 1) low back pain and stiffness for more than 3 
months that improves with exercise but not with rest; 2) limitation of motion of the 
lumbar spine in both sagittal and frontal planes; 3) limitation of chest expansion relative 
to normal values corrected for age and sex (Braun 2003 ACR Symposium). 
Differential Diagnoses for patients presenting with AS-like symptoms include 
rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, and diffuse idiopathic skeletal 
hyperostosis. 
1.1.6 Clinical Course, Outcome, and Treatment 
AS is characterized by inflammation of the axial skeleton, primarily the spine and 
sacroiliac joints in the pelvis (Laval et al., 2001). The inflammation is thought to come 
first in the disease progression, followed by joint erosion and finally ankylosis of the 
inflamed joints. The final stage of the disease may result in fusion ofthe entire spine, 
called bamboo spine, and complete loss of joint (Mori et al., 2003). 
Pain from spine inflammation is significant and persistent (Scalapino and Davis, 
2003). Pain associated with AS tends to be worse in the morning and after periods of rest 
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or inactivity and improves with exercise and movement. This pattern is the opposite of 
mechanical back pain, which improves with rest and intensifies with exercise. 
Treatment regimens vary depending on the severity of the disease. NSAIDs m 
combination with physical therapy and exercise regimens are the standard initial therapy 
for AS. 
Physical therapy has been shown to improve range of motion and maintain 
affected joint mobility as well as reducing pain symptoms (Uhrin et al., 2000). Standard 
physical therapy involves postural training, range of motion exercises and can involve 
hydrotherapy. Swimming is recommended to newly diagnosed patients as a way to 
maintain range of motion without putting strain on the joints. 
NSAIDs are initially effective in the treatment of AS. However, NSAID use may 
result in gastrointestinal disturbances. It has been reported that approximately 60% of AS 
patients experience adverse effects ofNSAIDs, while 50% do not achieve pain relief 
while on these medications (Scalapino and Davis, 2003). Selective targeting of the 
cyclooxygenase-2 pathway with the new COX2 inhibitors have reduced this toxicity but 
not improved efficacy in all users (Mease, 2003). 
When NSAIDs fail to control pain symptoms, disease modifying anti-rheumatic 
drugs or DMARDs are used as an alternate approach. While these drugs modify the 
course of inflammation, they often have deleterious side effects and primarily target 
peripheral joints. AS disease activity is predominantly axial, so for many AS patients, 
DMARDs are ineffective. All of these drugs treat the symptoms, not the cause, and do 
not prevent progression of the disease (Braun, 2003). Sulfasalazine and is a common 
DMARD used in AS for patients who fail NSAID therapy. Sulfasalazine has marginal 
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effects on axial symptoms, and is more linked to improvement of peripheral involvement. 
Side effects of sulfasalazine include nausea, dizziness, headache and rash, with more rare 
severe events of leukopenia and neutropenia. Pamidronate, a bisphosphanate, has shown 
promise in treating spondylitis in a subset of patients (Maksymowych et al., 2002). 
Corticosteroids such as prednisone are also commonly used when NSAIDs fail to 
relieve symptoms. Long term use is not recommended, however, due to the effects of 
steroid therapy on bone density. Methotrexate has not been shown to be efficacious in 
AS. 
The biologic compounds are designed to lower circulating levels of the 
inflammatory cytokine TNFa, and treat the cause ofinflammation (Braun, 2003). These 
agents are the best choice for AS patients who do not respond or have adverse events 
with conventional treatment. Indicators of a positive response to biologic agents, which 
was defined as a greater than 50% improvement in disease activity measured by the Bath 
ankylosing spondylitis disease activity index (BASDAI) within 12 weeks of treatment, 
included younger age, short disease duration, good functional ability (measured using the 
Bath ankylosing spondylitis functional index), elevated ESR and CRP, and higher disease 
activity (measured by BASDAI) (Rudwaleit et al., 2004). Side effects ofbiologic therapy 
are those of immunosuppression: opportunistic infections, reactivation of tuberculosis, 
multiple sclerosis-like symptoms, and malignancy. Also, as these drugs are relatively 
new, there is little data on effects of long term use. 
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1.2 ETIOLOGY 
AS is a complex multifactorial disease. Multiple risk factors with multiplicative 
effects are responsible for developing this disease. While most of these risk factors are 
unidentified, it is known that immunology, environment, and genetics all contribute to 
susceptibility. 
Pathologically, there are two key steps in the development of AS. The first is an 
autoimmune chronic inflammatory response at sites of enthesis. The second is the healing 
of these lesions by conversion of cartilage to fibrous tissue. Determining the factors 
responsible for these pathological steps is key to the understanding of the mechanism of 
AS development. 
1.2.1 Immunological 
What is known about the mechanism of AS points to a role for the innate and 
acquired immune response in its development. While the components of the immune 
response contributing to AS susceptibility are currently unknown, this is an area of 
intense research. 
One component of the immune system that has been linked to AS susceptibility is 
human leukocyte antigen B27. The HLA class I molecules function to present antigens 
from the cytoplasm to the cytotoxic CDS+ T cells of the immune system (Smith, 2002). 
The HLA-B27 allele in the major histocompatibility (MHC) region is strongly linked to 
AS. This HLA molecule has been observed to have more homology to bacterial proteins 
that the other HLA molecules (Ramos et al., 2002). The homology seen has led to 
theories of autoimmunity based on immune system stimulation by similar bacterial 
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peptides (Ramos et al., 2002). The HLA-B27 protein is a heterodimer of ~z­
microglobulin and an a-chain (Smith, 2002). The a-chain contains the antigen binding 
cleft used to present antigens to the circulating cytotoxic T .,cells. However, it is unknown 
whether it is a mutation in the HLA-B27 gene that is responsible for AS risk or a 
mutation in a gene tightly linked to HLA-B27 that is responsible. 
1.2.2 Environmental 
Evidence from animal models of AS and its common comorbidities shows a 
strong role of infectious agents in the development of disease. When animal models of 
Crohn's disease are raised in a germ-free environment, they do not develop disease while 
the litter-mates raised in a normal environment develop symptoms (Bonen et al., 2003). 
Similarly, HLA-B27 transgenic mice in sterile environments do not develop symptoms; 
but when removed from sterility, AS-like disease spontaneously develops. The 
involvement of microorganisms in developing disease implies a potential misregulation 
of the immune response which is triggered by exposure to a pathogen and leads to the 
autoimmunity seen in AS. The infection by specific microorganisms, which have yet to 
be identified, triggers the development of spondyloarthropathy (Rudwaleit et al., 2001 ). 
1.2.3 Genetic 
There are several lines of evidence that show AS has a strong genetic component. 
Heritability of AS is 90% as measured by twin studies (reviewed in Brown et al., 2003). 
Sibling recurrence risk ratio (A.s), which is the risk of developing the disease if you have 
an affected sibling divided by the population prevalence of the disease, is used as a 
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measure of the role genetics plays in disease susceptibility. This evidence has been 
gathered from population based studies, twin studies, association and linkage studies. 
Population based studies: Population based studies have determined the risk for 
developing AS if a sibling is affected is As = 82 in the British population, which is high 
compared to other rheumatologic disease such as rheumatoid arthritis (As= 14) (reviewed 
in Turesson and Matteson, 2006) and systemic lupus erythematosus (As= 24) (reviewed 
in Tsao, 2002). This is Risch's recurrence risk ratio, where the sibling risk (As) is 
calculated by determining the prevalence of disease among affected siblings and dividing 
by the population prevalence, which is often estimated. This estimation of the 
denominator introduces some error in the calculation as each population has a different 
prevalence of disease. This figure is dependent on the population being studied, and 
highly heritable diseases may have low sibling recurrence risks because of this bias. This 
bias does not apply here as the disease is rare, and thus has a low prevalence (around 
1: 1000). A Risch's recurrence risk ratio greater than two is considered indicative of a 
genetic component in the disease etiology. A As of 82 is very high, the highest known for 
any complex rheumatic disease, as most complex genetic diseases have values less than 
25. The sibling recurrence rate for the Newfoundland population has not been 
determined, but as the descent of this population is primarily from Britain and Ireland, the 
rate is potentially similar to the British population. 
Twin studies: Twin studies are used to determine whether a disease has genetic 
susceptibility factors. Concordance rates test the percentage of twins that have or develop 
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the disease if the other twin has a known diagnosis. Since twins are raised in the same 
environment and are exposed to the same extraneous risk factors, if there is a difference 
in concordance rates between monozygotic (identical) and dizygotic (fraternal) twins it is 
due to the shared genetic risk factors of the monozygotic twins. Twin studies have shown 
a concordance rate of 63% for monozygotic twins and only 27% for dizygotic twins, 
when both individuals are HLA-B27 positive (Tsui et al., 2003). This can be compared to 
concordance rates of 15.4% for monozygotic twins and 3.6% for dizygotic twins for 
rheumatoid arthritis (Silman et al., 1993), and 24% and 2% for systemic lupus 
erythematosus (Deapen et al., 1992). 
Association: Association studies using a candidate gene approach have yet to identify 
all the genes that contribute to AS susceptibility. HLA-B60/ IL-l gene cluster/ CYP450/ 
ANKH have all been linked to AS susceptibility (as reviewed in Wordsworth 1998; 
Maksymowych et al., 2006; van der Paardt et al., 2002; Brown et al., 2000; Timms et al., 
2003). However these genes are associated with a low relative risk, it is hard to know 
significance of the functional consequences, and these results have not been validated. 
Association studies take unrelated cases and compare genotype frequencies to that of the 
general population for candidate genes chosen arbitrarily based on what is known about 
the mechanism of disease. Genes that have been examined with respect to AS to date are 
primarily involved in the inflammatory immune response. 
Linkage: Linkage studies take large families with multiple affected members in 
multiple generations and examine if molecular markers are distributed differently in 
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patients with the disease as compared to those without the disease. The areas determined 
using genome wide scans, which use many markers over the entire genome in an assay, 
tend to be broad regions. Fine mapping of these regions can then be performed using 
many markers with smaller distance between them within the broad region, or a directed 
linkage scan. Large numbers of patients are required to adequately perform a genome-
wide scan that is generalizable to a population. Several chromosome arms outside the 
major histocompatibility complex region ( 6p) have been identified as potential linkage 
sites for AS (van der Paardt et al., 2002). Regions identified as contributing to AS 
susceptibility are on chromosomes 1p, 2q, 9q, 10q, 16q, and 19q (reviewed in Sims et al., 
2004). Other identified areas are linked to severity measures such as the Bath AS scales 
(the Disease Activity Index, and Functional Index). The BASDAI has been linked to 
chromosomes 11q, 16p, 18p and 20q. The BASFI was linked with chromosome 2q. Age 
of onset was linked with chromosome 11 q. Regions on 3p, 11 p, 11 q, 16p, and 18p were 
linked with more than one phenotype (reviewed in Sims et al., 2004). 
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1.3 IDENTIFICATION OF SUSCEPTIBILITY GENES 
Traditionally, there are two main methods in genetic study design: linkage studies 
and association studies. Linkage studies can be divided by sibling pair or traditional 
multiplex approach. The traditional multiplex approach uses large families with multiple 
generations to create a model for the inheritance of the disease. This method is highly 
successful for monogenic disorders that follow Mendelian transmission. Unfortunately 
there has been some difficulty adapting this model to analyze susceptibility for complex 
models of disease that involve more than one genetic loci or varying disease penetrance. 
Assumptions about candidate gene frequency, mode of transmission, penetrance of 
disease, phenocopy rate and marker allele frequency are necessary to create a model of 
inheritance. As the inheritance of the disease grows more complex the more error is 
introduced in making these assumptions. This method is also dependent on the family 
being studied and the quality of information obtained about multiple generations. Sibling 
pair studies are model independent and relatively easy to collect samples for, however, 
success is modest and for complex diseases with a relative risk less than two, these 
studies don't produce replicable results. Diseases with a low relative risk are by definition 
rare as the risk of a random sample developing the disease is low. Linkage studies are 
very powerful for monogenic diseases, but the power drops as the complexity of the 
disease increases. Problems arise when using linkage studies to analyze complex diseases 
in the following situations: incomplete penetrance of the gene, i.e. the phenotype (visible 
expression) varies despite having the genotype; phenocopies, i.e. the disease phenotype is 
also associated with factors other than the gene being studied; genetic heterogeneity, i.e. 
more than one loci independently cause disease; environment interactions, i.e. an 
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environmental trigger contributes to disease susceptibility; and insufficient recruitment of 
family members. These problems can also be seen in association studies but can be more 
effectively managed with population selection by selecting a population with 
homogenous genetic heritage and homogenous environment. Recruitment of family 
members is not an issue in association case control studies as the samples should not be 
related to maintain independence. As AS is a complex disease with a multigenic etiology 
and a low relative risk, linkage studies are less powerful for identifying susceptibility 
genes with the available number of patients. 
The benefit of performing an association study for diseases where the relative risk 
is less than two is that sample sizes do not need to be as large and large families are not 
required, as illustrated in Figure 1 (Risch, 2000). Association studies can be divided into 
two main methods; case control, and family based, which is analyzed by transmission 
disequilibrium tests (TDT). TDT studies analyze trios, an affected child and his/her 
parents, for transmission of the affected haplotype from parent to child. Case control 
studies are more representative of the general population studied than TDT or linkage 
studies, which provide results specific for a single large family. Case control is a good 
method for diseases with a low relative risk, with smaller sample sizes needed than 
linkage studies for these diseases (Risch, 2000). Controls should be unrelated individuals 
from the same population to maximize statistical significance while maintaining smaller 
sample sizes (Risch, 2000). One disadvantage to using a case control approach is a higher 
number of false positives when examining genetic association to disease than other study 
designs, in other words showing association when in truth none exists. However, there 
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Figure 1: Comparison of sample sizes between association and linkage studies 
by relative risk of disease (from Risch, 2000). The dotted line 
represents linkage studies while the solid line represents association 
studies. 
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are true positives coming out of these studies and false results can be minimized with 
careful design and multiple testing statistics. 
1.3.1 Study Design 
To best utilize the Newfoundland AS population to assess genetic association 
with disease, a case control association study with a candidate gene approach was used. 
This approach is more feasible in the Newfoundland population because the available 
affected population is from multiple small families with only one or two generations of 
affected family members, which would make a linkage study more difficult. As AS has a 
relative risk in the general population less than two, case control is a good method to use 
with the sample size available (Risch, 2000). For a genetic study such as this, it is 
possible to use prevalent cases of the disease. Incident cases are ideal for most 
epidemiological studies due to the defined onset of disease, and the knowledge that all 
patients in the case group are at the same stage in disease progression. However, as the 
genetic makeup of an individual will not change with time or disease stage, it makes no 
difference how long the patient has had symptoms. 
Candidate genes tend to be chosen based on position or function. This means that 
genes selected for studies are either physically located near genomic regions linked to AS 
through previous linkage studies, or the gene product has a biological function that 
logically could link it to the disease. Linkage studies have shown that the MHC region, as 
well as several areas outside the MHC region are linked to AS. Further discussion of each 
gene chosen, including the rationale for the polymorphisms examined, is contained in the 
following section. 
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The candidate genes were arbitrarily separated into several categories relating to 
the pathological steps in development of AS. These are cytokines which link the innate 
and acquired immune responses, signalling molecules involved in the innate immune 
response to bacteria, and genes that have been linked to bone disease that are potentially 
involved in the conversion of cartilage to fibrous tissue. 
Cytokines are the messengers of the immune system. As AS is an autoimmune 
disease, problems within the immune system of these patients exist. The cytokine release 
pattern in AS is predominantly TH2 with impairment ofthe TH1 response (Baeten et al., 
2001). The TH2 subset ofCD3+ T cells are involved with the inflammation seen in 
allergy. 
Evidence from animal models of AS and its common comorbidities shows a role 
for infectious agents in the development of disease. The involvement of microorganisms 
in developing disease implies a potential misregulation of the immune response which is 
triggered by exposure to a pathogen and leads to the autoimmunity seen in AS (Rudwaleit 
et al., 2001). Signalling molecules involved in stimulating the immune response to 
microorganisms are thus logical candidates for study in this disease. 
The bulk of research published regarding AS targets the inflammation aspect of 
the disease, as proteins involved in the immune response are the common candidates. 
However, as previously stated, AS is a disease with two main stages, those of 
inflammation, which presents first, and ankylosis, which is the end stage of the disease. 
The ankylosis of AS has not been studied in depth, and logic dictates that susceptibility to 
AS must include genes that promote ankylosis, as all of the inflammatory arthropathies 
have inflammation, but only AS has fusion ofthe inflamed joints. Thus, as a subset of 
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this project, several candidate genes involved in bone disease were chosen based on 
locations identified in genome-wide scans to be linked to AS susceptibility. 
Analysis ofgenetic association to disease was performed using single nucleotide 
polymorphisms (SNPs). SNPs are naturally occurring variants in genes within the human 
genome. While some SNPs cause functional variants of proteins with varying effects of 
biological function, most are silent, in that they do not change the ultimate amino acid 
sequence of the gene product. Functional variants are ofhigher interest due to these 
potential effects on biological function which could explain the misregulation that leads 
to development of disease. Also of interest is SNPs of the promoter regions of genes 
which could alter the amount of protein being transcribed by interfering with 
transcription factors and thus mRNA production. 
1.3.2 Candidate genes 
1.3.2.1 Genes within the MHC region 
The MHC region on chromosome 6p remains the most strongly linked region to 
AS in genome wide scans. Over ninety percent of AS patients test positive for the HLA 
B27 allele (Tsui et al., 2003). The population frequency of this allele is six to nine 
percent in Caucasian populations. However, only an estimated nine percent of all HLA-
B27 positive individuals develop AS. The presence of the HLA-B27 allele only accounts 
for sixteen percent to thirty three percent of the genetic basis of this disease (Sims eta/., 
2004; Brophy eta/., 2003). Thus, there are more genes to be discovered that confer risk 
to the development of this disease. The association with chromosome 6p may be due to 
the presence ofHLA-B27, but research has been focused in this region for additional 
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susceptibility genes for AS. As there is some debate whether or not it is HLA-B27 and 
not a gene tightly linked to it that confers genetic risk, examining genes in this area is of 
scientific merit. 
TNFalpha 
Tumor necrosis factor alpha (TNFa) is a cytokine with multiple functions that is 
constitutively expressed by adipose tissue and selectively released by cells of the immune 
system as part of the immune response (Lee et al., 2000). The major source ofTNFa in 
the body stems from activated macrophages (Field, 2001 ). Treatment of cells with TNFa 
results in the activation ofNF-KB through dissociation ofiKB, the inhibitory subunit of 
the protein complex (Rosenstiel et al., 2003). TNFa has been shown to upregulate cell 
signaling molecules such as CARD15 through increased mRNA expression in a manner 
dependant on time and concentration ofTNFa used (Hisamatsu et al., 2003). 
The role ofTNFa in AS is only now being explored. TNFa levels are elevated in 
AS patients, and this cytokine is released by the helper T cells that are associated with the 
disease (Braun et al., 2003). mRNA has been found in the inflamed sacroiliac joint 
characteristic of AS (Field, 2001 ). Biopsies of inflamed sacroiliac joints in AS patients 
have shown increased levels ofTNFa around sites of ectopic bone formation (McGarry 
et al., 2001; Zhang etal., 2003). Genetic studies ofTNFa SNPs have been inconclusive 
in determining association with AS. It is apparent that population plays a role in 
association as much of the conflicting evidence is from different cultural groups. TNFa 
would be a logical candidate gene to study due to the marked efficacy ofthe anti-TNFa 
therapies in these patients. TNFa is located within an area identified by genome wide 
scan as linked to AS, 6p21. 
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Polymorphisms to be examined within this gene are located in the promoter at 
positions -238, -308, -857, -863, and -1031. The promoter polymorphisms would most 
likely affect the regulation of the gene. They would not have any effect on function as 
they are outside of the sequence of the TNFa protein. These polymorphisms were chosen 
because TNFa protein levels are elevated in AS patients, implying a potential defect in 
regulation. Polymorphisms at positions -238 and -308 are thought to lead to decreased 
transcriptional activity ofTNFa, and a lower response against antigen stimulation 
(Kaluza et al., 2000), while polymorphisms at positions -857, -863 and -1031 have been 
associated with increased TNFa production (Soga et al., 2003). Separately, these 
polymorphisms have been examined in several populations (Caucasian and Asian 
primarily) with respect to several immune-mediated diseases, such a celiac disease, IBD, 
Graves disease, and psoriatic arthritis. While the SNPs at -238 and -308 have been 
studied before in AS patients of Dutch, Spanish, German, and Scottish descent with 
conflicting results, the SNPs at the other three positions have not yet been examined in 
AS (Milicic et al., 2000; Fraile et al., 1998; Hohler et al., 1998; McGarry et al., 1999; 
Verjans et al., 1994; Field, 2001). 
1.3.2.2 Genes outside the MHC region 
At least half of the genetic risk for developing AS is estimated to come from 
factors outside the MHC region (Jaakkola et al., 2004). To date, many candidate genes 
have been examined, but no conclusive susceptibility genes have been named. Much of 
the MHC region is in linkage disequilibrium with the HLA molecules, where linkage 
disequilibrium is the inheritance of genes in linked segments. For example, it may be 
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shown that gene A is associated with AS, but gene A is only inherited along with gene B, 
which is the true disease susceptibility gene. Since HLA-B27 is known to be associated 
with AS, any gene that is inherited along with B27 may be associated with AS only due 
to this linkage as opposed to function. The non-MHC region thus provides an area to 
study where the results cannot be linked to HLA status and falsely reported as positive 
associations. 
1.3.2.2.1 Cytokines 
Cytokines are messengers of the immune system that link the innate and acquired 
immune responses. These small molecules have pleiotrophic effects on several cell types, 
often inducing a characteristic response in different cells by activating linked second 
messenger pathways. Cytokines are divided into categories based on similar functions 
and characteristics. Cytokines that are logical candidates for AS research include 
proinflammatory cytokines, such as IL-l and TGF-~, and anti-inflammatory cytokines, 
such as IL-l 0, in which functional variants could affect regulation of the immune 
response to the responsible microbial trigger of AS. 
IL-l: The Interleukin-1 gene cluster is located on chromosome 2q14, which has 
been identified by genome wide scan as a potential linkage region to AS (van der Paardt 
et al., 2002). One susceptibility loci for AS is located 0.3 centimorgans from the IL-l 
gene cluster (Ravindran eta/., 2004). Strong linkage disequilibrium exists between genes 
in this cluster in the Dutch Caucasian population, and associations found in this region 
are questionable as the polymorphisms may be linked to a disease causing allele (van der 
Paardt eta/., 2002). Interleukin-1 is a potent proinflammatory cytokine and is thought to 
have a key role in joint inflammation (Cantagrel eta/., 1999). 
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Interleukin-1 a and p are inflammatory cytokines involved in the immune 
response. Interleukin-1 a and p have been associated with juvenile chronic arthritis and 
with joint erosion in RA (Djouadi et al., 2001). The proinflammatory cytokines promote 
the inflammation changes seen in AS, and eventually will lead to destruction of bone and 
cartilage (Crawley et al., 1999). The gene cluster was recently associated to ankylosing 
spondylitis in three Canadian populations (Maksymowych et al., 2006). Interleukin-1 p 
has been previously implicated in destructive joint changes (Maksymowych et al., 2003). 
Polymorphisms in this gene have been linked to IBD (van der Paardt et al., 2002). 
Interleukin-1 receptor antagonist (IL-lRa) works to antagonize IL-l signaling by 
competitive inhibition. This protein provides a natural competitive inhibitor of the IL-l 
response. IL-l Ra binds to the Interleukin-1 receptor but does not induce a signaling 
response. Recombinant IL-lRa is currently being evaluated at the clinical trial level for 
treating the inflammatory arthropathies (Cantagrel et al., 1999). Polymorphisms in the 
IL-lRa gene have been related to Multiple Sclerosis and IBD, which are both chronic 
inflammatory diseases (van der Paardt et al., 2002). A recent study found polymorphisms 
in IL-lRa associated with AS, including a variable 86 base pair repeat in intron 2 
(Maksymowych eta/., 2003). The authors concluded that the association was likely due 
to linkage disequilibrium with an unidentified primary disease locus. Scottish and Dutch 
studies have shown association with the repeat allele 2 of IL-l Ra and AS, but there have 
been problems in replicating these findings with other studies (Breban et al., 2003; 
McGarry et al., 2001). The repeat allele 2 has been reported to increase IL-lRa 
production, and has been associated with juvenile idiopathic arthritis, psoriasis, ulcerative 
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colitis, alopecia areat, lichen sclerosus, systemic lupus erythematosus, and diabetes 
(Vencovsky eta/., 2001; Breban et al., 2003; Djouadi eta/., 2001). 
IL-10: Interleukin 10 is an anti-inflammatory cytokine that acts to inhibit the 
inflammatory response. This cytokine has been shown to inhibit the antibacterial 
response by macrophages (Yu and Kuipers, 2003). IL-10 is produced by TH2 T cells to 
suppress stimulation of the T H 1 response. Since the response seen in AS patients is 
primarily T H2 in nature, cytokines produced by these T cells may be disrupted in AS 
patients. Interleukin-1 0 has been linked to joint destruction in RA, though this has been 
disputed (Huizinga et al., 2000; MacKay eta/., 2003). IL-l 0 was shown to inhibit the 
production of pro inflammatory cytokines and the proliferation ofT H 1 lymphocytes. The 
addition of exogenous IL-l 0 to rodent models of chronic arthritis protected against bone 
destruction (Huizinga eta/., 2000). The production ofTNFa and IL-l, other candidate 
genes being studied in this project, are inhibited by IL-10 in vivo (Huizinga et al., 2000). 
The inhibition of IL-l is achieved by upregulating release of soluble IL-lRa (Crawley et 
al., 1999). TNFa is inhibited by IL-10 action both at the level of synthesis and by 
inhibiting release of mature TNFa from leukocytes (Crawley et al., 1999). IL-l 0 is 
produced by monocytes and B cells, and its release triggers a potent increase in 
production and differentiation of B cells, characteristic of the humoral response triggered 
by TH2 signaling (MacKay et al., 2003). 
Control of IL-l 0 production appears to occur at the transcriptional level (Crawley 
et al., 1999). Promoter polymorphisms are located within putatative transcription factor 
binding sites (Crawley et al., 1999). In AS patients the level ofiL-1 0 secretion by 
cytotoxic T cells is significantly higher than in controls regardless ofHLA-B27 status 
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(Goedecke et al., 2003). Studies have suggested a minimal role for IL-l 0 polymorphisms 
in AS in the Finnish population, but as the evidence is not supported with replicated 
studies, examination of potential functional polymorphism variants is warranted. 
TGF-p: The TGF~ gene is located on chromosome 19, where a genome wide scan 
has identified a potential AS candidate region in the English and Finnish populations 
(Jaakkola et al., 2004). TGF~ is a cytokine that is involved in the inflammatory response, 
tissue fibrosis and bone remodelling (Jaakkola et al., 2004). TGF~ is also involved in 
osteoblast development (Zhang et al., 2003). Defective TGF~ 1 is associated with 
Camurati-Engelmann disease, an autosomal dominant disease characterized by 
hyperostosis and sclerosis of the diaphyses oflong bones (Janssens et al., 2003). TGF~l 
is released by macrophages, lymphocytes, and chondrocytes. This production by 
chondrocytes is intriguing as the conversion of cartilage to fibrous tissue likely occurs in 
AS. Detectable levels ofTGF~ are found in biopsies of AS inflamed sacroiliac joints near 
sites of ectopic bone formation (Zhang et al., 2003). This evidence suggests a role for 
TGF~ in the ankylosis of AS. SNPs to be examined for this study include three promoter 
polymorphisms and one polymorphism within the first exon, all of which theoretically 
have functional consequences. 
1.3.2.2.2 Signalling molecules 
Molecules involved with the innate immune response to enteric bacteria are a 
logical choice for study in AS patients for two key reasons. The first is the apparent 
microbial trigger of AS development (reviewed in Rudwaleit et al., 2001). If the response 
to the unknown microbe is impaired, the microbe would remain in the system longer and 
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have access to the mechanisms that lead to autoimmunity. The second reason supporting 
this area of research is the high prevalence of subclinical inflammatory bowel disease in 
AS patients (Baeten et al., 2002). This subclinical IBD may result from improper 
clearance of foreign enteric flora. 
CARD15: Caspase recruitment domain-containing protein 15 (CARD15) is 
associated with Crohn's Disease, a common comorbidity of AS. This gene contributes 
approximately forty percent of the genetic susceptibility to Crohn's Disease (Martinet 
al., 2002). 
The gene for CARD15 is located on chromosome 16 (16p12-q21), which is the 
chromosomal region commonly identified in genome wide scans for AS susceptibility 
genes with the highest likelihood of odds (LOD) score of 4.7 (Laval et al., 2001; van der 
Paardt et al., 2003). Expression of the CARD15 protein is intracellular, with primary 
expression in monocytes (Bonen et al., 2003). It has been shown that CARD15 mRNA 
and protein levels are specifically upregulated in intestinal epithelial cells by TNFa 
(Rosenstiel et al., 2003; Gutierrez et al., 2002). The current consensus is that CARD15 
acts to enhance inflammation through activation ofNuclear Factor-kappa B (NF-kB) 
upon stimulation with bacterial proteins, primarily those of the bacterial coat; 
lipopolysaccharide (LPS) and peptidoglycan (PGN) (Gutierrez et al., 2002; Inohara et al., 
2003). CARD15 is also upregulated by NF-KB, through a NF-KB transcriptional 
activation sequence in the CARD15 promoter (Gutierrez et al., 2002). The variants of 
CARD15 determined by Hugot et al. to be involved in Crohn's disease are to be studied. 
The common CARD15 variants associated with Crohn's Disease are not found in 
the Asian population (Inoue et al., 2002; Yamazaki et al., 2002). This fact is important to 
27 
note for research in genetic susceptibility, as it illustrates genetic linkage to disease varies 
with ethnic group. Also of interest is the fact that the incidence ofCrohn's Disease in the 
Japanese population is ten times less than the rates in Western populations, but has 
increased steadily during the past few decades (Inoue eta/., 2002). This increase could 
potentially be due to changes in diet and environmental factors to more closely resemble 
that of Western populations. 
The 1007fs (frameshift mutation at position 1007) variant ofCARD15 (also 
denoted as 3020insC), results in a truncated CARD15 protein at the C-terminal LRR 
domain (Bonen eta/., 2003). CARD15 recognizes the base unit of peptidoglycan (PGN) 
common to all bacteria, muramyl dipeptide (MDP) (Girardin eta/., 2003a). The 1 007fs 
truncated protein is unable to activate NF -kB optimally upon stimulation by 
lipopolysaccharide (LPS), and is almost entirely unresponsive to MDP in vitro 
(Chamaillard eta/., 2003; Girardin eta/., 2003b). This reduction in activity is somewhat 
controversial as studies using colonic tissue from Crohn's Disease patients show 
increased NF-KB levels (van der Linde eta/., 2003). It has also been found that CARD15 
molecules lacking the C-terminal LRR domain are still capable of activating NF-kB 
through unspecific stimuli (Kabesch eta/., 2003). This mutation has been associated with 
significantly higher circulating levels of IgE, the immunoglobulin associated with allergy 
(Kabesch eta/., 2003). With respect to Crohn's Disease, the 1007fs mutation has been 
associated with fibrostenosing disease regardless of ethnic variation (studied in Jewish 
and Caucasian populations) and earlier age of onset in the Irish population (Abreu eta/., 
2002; Bairead eta/., 2003). Prevalence of this mutation is three percent in the European 
population (Marsh and McLeod, 2003). 
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Two other common variants in CARD15, G908R and R702W have been 
associated with Crohn's Disease (Bonen et al., 2003). These variants respond to bacterial 
LPS and PGN, but have impaired NF-kB activation. The R702W mutation has been 
linked to a two-fold risk of allergic rhinitis, and the G908R mutation has been associated 
with a three-fold increase in risk of developing allergic rhinitis and a two-fold risk of 
developing atopic dermatitis as an allergic response (Kabesch et al., 2003). Prevalence of 
the G908R mutation in the European population is three percent, while prevalence of the 
R702W mutation in this population is two percent. 
The CARD 15 variants have been examined for association with AS. No 
association between these variants and AS has been shown to date (Crane et al., 2002). 
However, the populations studied have been heterogeneous in nature, and analysis by 
ethnic group has not been performed. 
TLR4: Toll-like Receptor 4 (TLR4) is a protein with function similar to CARD15 
(Inohara et al., 2003). The two proteins recognize different elements of bacterial antigens 
and stimulate the innate immune response through NF-KB. Where CARD15 is thought to 
primarily recognize peptidoglycan, TLR4 primarily recognizes lipopolysaccharide (LPS) 
(Rehli et al., 2000). TLR4 is located on chromosome 9q32-33, which was identified in 
genome wide scans for AS susceptibility (reviewed in Sims et al., 2004). The commonly 
studied polymorphisms Asp299Gly and Thr399Ile will be examined in this study. These 
single nucleotide changes negatively affect reponsiveness to LPS. This gene has recently 
been studied with respect to AS (van der Paardt et al., 2005). The Asp299Gly variant was 
examined in 113 Dutch AS patients. The p-value was not significant, but the authors 
caution small numbers may be responsible for the lack of significance. The Asp299Gly 
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variant was recently shown to be associated with protection against Rheumatoid Arthritis 
but did not affect disease severity (Radstake et al., 2004). The recent study of this gene in 
AS patients with questionable results supports our choice of these polymorphisms as 
candidates for AS susceptibility in our study. 
TLR4 stimulates the immune response to LPS via stimulation ofNF-KB which 
induces transcription of pro-inflammatory cytokines such as TNFa and activates narve T 
cells (Palsson-McDermott and O'Neill, 2004). LPS is a major component of Gram 
negative cell walls. Aside from LPS, TLR4 also recognizes lipoteichoic acid, endogenous 
heat shock protein 60 ligands (HSP60), fibronectin, and hyaluronic acid (van der Paardt 
et al., 2005). 
Allele frequency of the Asp299Gly polymorphism was recently found to be 
associated with Crohn's Disease in the Greek population (Gazouli et al., 2005). Crohn's 
disease is a common comorbidity of AS. Due to the high prevalence of subclinical gut 
inflammation in AS patients ( 60% ), looking to genes known to be involved in the 
pathogenesis of gut inflammation for potential involvement in AS is logical. 
1.3.2.2.3 Genes Involved in Bone Disease 
Most of the research concerning AS to date investigates the inflammatory 
response in AS. The pathological step involving the conversion of cartilage to fibrous 
tissue and ectopic bone formation is poorly understood. The mechanism of this pathology 
is largely unknown. Genes were chosen based on location in susceptibility regions 
identified by genome wide scans, functional involvement in bone remodeling, or when 
known mutations are linked to bone disorders. As AS is one of many inflammatory 
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spondyloarthropathies, but is unique in that there is new bone formation, it is logical that 
part of the genetic susceptibility to AS development includes genes that predispose to 
ectopic bone formation. 
FGFR2: Fibroblast growth factor receptor 2 (FGFR2) is located on chromosome 
10, which has been linked to AS through genome wide scans (reviewed in Sims eta/., 
2004 ). This protein is a receptor for fibroblast growth factor and defects in this gene are 
responsible for the bone disorders Crouzon syndrome, Jackson-Weiss syndrome, Apert 
syndrome, and Pfeiffer syndrome (MIM:123500; MIM:123150; MIM:101200; 
MIM:101600). These diseases are all characterized by craniosynostosis, the early fusion 
of the infant skull. Of interest to this study, Pfeiffer syndrome is also characterized by 
ankylosis, particularly of the elbow. The SNPs being examined from this gene were 
chosen based on potential functional consequences of polymorphism, all are located 
within exons of the gene. 
ALX4: Aristaless-like homeobox 4 (ALX4) is a transcription factor located on 
chromosome 11, which has been linked to AS through genome wide scans, as well as 
being linked to BASDAI scores and age of onset (reviewed in Sims eta/., 2004). This 
protein is thought to be involved in skull and limb development. Defects in ALX4 are 
responsible for parietal foramina 2, an autosomal dominant disease characterized by 
deficient ossification of the parietal notch of the skull (Mavrogiannis et a/.,2001). 
Expression of this protein is restricted to bone, making it an attractive candidate for bone 
disease susceptibility. The SNPs chosen for examination are all located within exons. 
DLL3: Delta-like three (DLL3) is a ligand for the Notch receptor located on 
chromosome 19. Mutations in this gene are responsible for spondylocostal dystosis 
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(Whittock et al., 2004). The polymorphisms chosen to examine this gene are a frameshift 
polymorphism in exon 2 and a singe nucleotide polymorphism in exon 6. 
TCIRG 1: T -cell immune regulator 1 (TCIRG 1) is located on chromosome 11. 
Mutations in TCIRG 1 have been linked to infantile malignant osteopetrosis, a disease 
characterized by bone thickening. The TCIRG 1 gene is expressed in osteoclastomas and 
the thymus. A polymorphism of the promoter was found to be associated to lower bone 
mass in women (Sobacchi et al., 2004). The SNPs chosen for examination in this study 
have potential functional consequences, rs7479081, rs2471829, and rs1047817 are located 
within exons. 
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1.4 POTENTIAL BENEFIT 
There are three main benefits to pursuing this research. Firstly, identifying genes 
associated with AS will add to knowledge about the disease once the functional 
consequences are inserted into the known stages of pathogenesis. Secondly, genes 
involved may be used to predict course and outcome in individual patients with the 
disease. Thirdly, identifying susceptibility genes provides potential targets for directed 
treatments such as the anti-1NFa biologics that may prove to be more effective in 
treating the disease. 
AS is a disease with an early age of onset. This early age often leads to a long 
delay between symptom onset and diagnosis. This delay has been reported to be an 
average of 5-7 years (Braun, 2003). Early treatment and education about exercise 
techniques and posture has been shown to slow the progression of the disease and 
maintain function of the spine (Scalapino and Davis, 2003). The primary test for 
diagnosis of AS is a positive X-Ray for inflammation in the sacroiliac joint. This 
inflammation occurs once the disease has progressed to a certain point, leaving a need for 
an earlier indicator of disease so that treatment can begin as soon as possible (van der 
Heijde, 2003). Epidemiological studies show that the principal amount of damage and 
decline in function happens during the first ten years of disease, especially in those 
patients with severe involvement (Landewe et al., 2003). The identification of genetic 
risk factors would help in early diagnosis, and if conducted prior to symptom onset can 
be used preventatively to spur radiological testing at the first sign of symptoms. This 
early diagnosis would aid in maintaining function, preventing fusion and improving 
quality of life in AS patients. 
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1.5 OBJECTIVE 
The objective of this study is to identify and test potential candidate genes for 
susceptibility to AS in the Newfoundland population. Candidate genes were chosen based 
on functional relevance to the disease phenotype of autoimmune inflammation and bone 
remodeling or positional proximity to regions previously linked to AS in other studies. 
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Chapter 2 Methods 
2.1 Population 
Choice of population is important in association studies. With respect to genetics, 
populations often differ in associated risk factors for disease. In AS there are reported 
differences in the prevalence ofHLA-B27 in different ethnic groups. In the Caucasian 
population, over 90% of AS patients are HLA-B27 positive. In African-Americans this 
prevalence drops to only approximately 50% of AS patients (Mijiyawa et al., 2000). The 
disease is phenotypically the same in these two groups, so there must be different genetic 
risk factors, or at least different risk contributions from genetic risk factors. Population 
stratification is a common confounder in case control studies. This confounder occurs 
when the cases and controls are not from the same genetic background. This is less of a 
concern in a founder population such as Newfoundland. 
Newfoundland is a founder population, which means that the population 
descended for the most part from the same core group of original settlers. From census 
data, it has been determined that the population ofNewfoundland grew from around 
20,000 settlers from Ireland and Britain in 1760 to 200,000 in 1890, largely due to natural 
expansion as the immigration rate was low during this time (Rahman et al., 2003a). 
Newfoundland communities have historically been geographically isolated with most 
individuals remaining where they were born. The main advantage of a founder population 
is a relatively homogenous group genetically which leads to a reduction in the genetic 
heterogeneity seen from ethnic differences (Rahman et al., 2003a). This reduction in 
heterogeneity makes the signal of a minor susceptibility gene easier to read and 
determine to be significant. This advantage has been utilized by several groups to identify 
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susceptibility genes for many conditions such as Crohn's disease, Bardet-Biedl 
syndrome, and hereditary non-polyposis colorectal cancer (reviewed in Rahman eta/., 
2003a). Incidentally, the first ever linkage study in AS was with a Newfoundland family, 
noting linkage to the MHC region (Rubin et al., 1994). Linkage disequilibrium, the non-
random association of genetic alleles, in young founder populations also makes it easier 
to find genetic association to disease, as the area that is linked through linkage 
disequilibrium tends to be larger in these populations. This linkage works to the 
advantage of studies in that it is easier to find a signal in a region in which susceptibility 
lies. However, it must be remembered the susceptibility may not be linked to the site 
tested, but instead a more distant site that is linked to the tested site through linkage 
disequilibrium. Genetic drift is the change in prevalence of genetic alleles often seen in 
founder populations. Genetic drift results in increased incidence of genetic disorders in 
these populations (reviewed in Rahman eta/., 2003a). This increased incidence of disease 
makes this population ideal for the study of rare diseases, such as AS, as the patient base 
will be higher. 
Any population based association study can only claim to identify susceptibility 
genes for the population tested. As there are differences between populations, 
generalizing results to other ethnically diverse populations cannot be done without further 
testing. Thus, a limitation of the Newfoundland population is that the results are only 
generalizable to Caucasian populations, specifically of Irish and English origin, and 
further study in different ethnicities is needed to verify the findings for other populations. 
This limitation is acceptable, however, because it will identify strong potential candidates 
for study in an area where few strong candidates are apparent. 
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The other advantage of using Newfoundland as a study population is the 
environmental matching of cases and controls. There is relative homogeneity in the 
environment and living conditions throughout the province. This is an advantage again 
over a major centre such as Toronto, which would have to deal with potential 
confounders such as urban pollution when assessing risk. 
2.2 Analysis Plan 
Unless there is selection pressure present in the population, allele frequency is 
found in an equilibrium defined by p2 + 2pq +q2=1, known as the Hardy Weinberg 
equilibrium. The first analysis performed on each set of results is a test for Hardy 
Weinberg equilibrium. The expectation is that controls would satisfy the equilbrium. 
The primary outcome is the association of genotype to disease. This analysis is to 
be performed using the chi-squared statistical test. The number of minor alleles in both 
groups out of total alleles present will be used to determine association. The test will be 
two tailed since the minor allele may be associated with the control group or the case 
group and thus be either a protective factor or risk factor for the disease respectively. 
Nonparametric statistics are used to examine the association between a categorical 
independent variable and nominal or ordinal dependent variables. In the primary outcome 
of this study both variables were nominal, genotype and disease status. The best test to 
analyze this data was the chi-square test. If the frequency for any cell was less than 5, 
Fisher's Exact Test was used. Significant associations will then be corrected for multiple 
testing using logistic regression which will also ensure that association with one allele 
was not due to association with another allele through linkage disequilibrium. 
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If an association of genotype to disease is found, secondary analysis will examine 
potential association with common phenotypic information, such as gender, age of onset, 
and disease severity (as measured by the validated disease activity scales). This analysis 
will be performed using appropriate statistical techniques, primarily logistic regression. 
Logistic Regression is an extension of multiple regression that can be used when the 
outcome is categorical. 
2.3 Clinical 
2.3.1 Patient selection criteria 
To be included in this study, patients had a definite diagnosis of ankylosing 
spondylitis, were over the age of 18, were at least third generation Newfoundlander, and 
were able to give informed consent. Patients were excluded if they had family members 
included in the study, as the samples must be independent. Patients used in this study 
were enrolled over the period from April 2003 to August 2004. Patients who wished to 
take part in the study spent approximately 45 minutes completing a questionnaire, 
medical history, donating a blood sample, and had assessments on their disease status 
performed by a research nurse and the investigator. Patient questionnaires were collected 
by Tara Snelgrove, physical data and blood samples were collected by research nurses 
Yvonne Tobin and Maxine Kelly. 
Ank:ylosing spondylitis was diagnosed in patients using the modified New York 
criteria. To be diagnosed with ankylosing spondylitis by these criteria, patients must have 
had radiological evidence of sacroiliitis (at least grade II bilaterally or grade III-IV 
unilaterally), and must have had at least one ofthe following clinical criteria: 1) low back 
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pain and stiffness for more than 3 months that improves with exercise but not with rest; 
2) limitation of motion of the lumbar spine in both sagittal and frontal planes; 3) 
limitation of chest expansion relative to normal values corrected for age and sex (Braun 
2003 ACR Symposium). 
The samples used as a control population were from healthy volunteers from the 
Newfoundland population collected for previous research with Dr. Rahman. The 
volunteers had no evidence of AS and as a group was of similar average age as the case 
group. Using a population control eliminates Berkson's selection bias in case-control 
studies, which is a bias in participant selection where the control population is at a 
different risk of exposure to risk factors for the disease than the cases. Controls will not 
be matched by case, as there are problems in genetics from over matching. If the 
difference between groups is too narrow, it becomes easier to miss differences due to 
disease processes. 
2.3.2 Ethical Considerations 
This study was approved with respect to ethical considerations by the Human 
Investigations Committee of Memorial University ofNewfoundland in 2000 as well as 
with the author as primary investigator in 2004 (study #04.116). Patients were enrolled 
after obtaining written informed consent and the wishes of the patient with respect to 
future use of their DNA was obtained in accordance with standard policy. Patient 
identifying information was kept in a locked cabinet in a locked room for the duration of 
the study and storage thereafter. 
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2.3.3 Patient information collected 
The questionnair~ consists of demographic information, a brief medical history, 
and validated scales of AS disease measurement. These scales are the BASDAI, the 
BASFI and the BASMI, as well as a brief quality of life index, the ASQoL. The measures 
of disease activity, functional index, physical impairments (or metrology index) and 
quality of life have all been previously validated (Bath Ankylosing Spondylitis Disease 
Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing 
Spondylitis Metrology Index, Ankylosing Spondylitis Quality of Life questionnaires 
respectively). These measures of disease severity and progression are included in the 
questionnaires so cases can be stratified by severity for phenotypic analysis for further 
analysis of any noted associations. The questionnaire is attached as Appendix A. A 
pedigree of affected relatives was obtained from each patient. 
2.4 Laboratory 
2.4.1 DNA extraction 
DNA extraction from the white blood cells in the blood sample and analysis was 
performed blind by Tara Snelgrove except in control data for TNFa., IL-l, IL-l 0, and 
CARD15, for which the allele frequencies were provided by personal communication 
from Dr. Rahman as these SNPs had already been genotyped in the control population by 
Lynette Peddle. The samples were given a study code and there were no identifiers to link 
severity of case to sample until after the genetic analysis was performed. 
DNA was extracted from 10 mL of whole blood collected in two 5 mL EDTA 
treated tubes for each participant using the Pmmega Wizard Extraction Kit. The whole 
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blood was spun at 2000 rpm for ten minutes. This separated the blood into three layers. 
The top layer of plasma was discarded and the layer of white blood cells, or huffy coat, 
was removed and combined for both tubes of blood. The huffy coat was then added to 30 
mL of cell lysis solution which breaks up any red blood cells that were extracted with the 
white blood cells. Red blood cells do not contain nuclei, and are thus unable to be used 
for extracting DNA. The cell lysis solution mixture is then incubated for ten minutes at 
room temperature, with gentle mixing to ensure lysis. The mixture is then centrifuged for 
ten minutes at 31 00 rpm. This produces a pellet of white blood cells. The supernatant, 
which consists of cell lysis solution and lysed red blood cells, is discarded and the pellet 
is resuspended by vortex. Nuclei Lysis solution is added to each tube (10 mL) and the 
solution is mixed by pipetting until the solution is homogenous. The solution is then 
incubated at 37°C for one hour, or until there are no visible clumps of pellet remaining. A 
protein precipitation solution is then added (3.3 mL) and the solution is vortexed until 
precipitate is observed. The samples are then centrifuged for ten minutes at 3100 rpm to 
create a pellet of precipitated protein. The supernatant is transferred to a clean 50 mL 
tube and 10 mL of isopropanol is added to precipitate out the DNA. The solution is 
gently mixed until precipitate is observed and centrifuged at 31 00 rpm for one minute. 
The supernatant is removed, and the pellet of DNA is washed with 10 mL of 70% 
ethanol. The solution is centrifuged at 3100 rpm for one minute and the ethanol wash is 
removed. The pellet is then incubated at 3 7°C overnight to dry the pellet and remove any 
residual alcohol. The dried DNA pellet is then resuspended with DNA rehydration 
solution, a buffer, by incubation at 60°C until the DNA pellet is no longer visible. The 
sample is then aliquoted into 1.5 mL tubes for future use. 
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Concentrations of extracted DNA were determined by spectrophotometry by 
creating a one in twenty dilution with rehydration solution and assessed for optic density 
which was then converted via spreadsheet into ng/JlL of DNA. Concentrations were used 
to dilute samples to 2.5 ng/JlL for mass array reactions, and 10 ng/J!L for gel 
electrophoresis genotyping. 
2.4.2 Sequenom MassARRA Y SNP Genotyping 
The Sequenom system uses matrix-assisted laser desorption ionization (MALDI) 
coupled with a time of flight (TOF) tube for spectral analysis of single nucleotide 
polymorphisms in DNA fragments amplified by polymerase chain reaction (PCR). 
Equipment used includes a Bruker Biflex mass spectrometer, a Beckman multimek robot 
for liquid handling, the custom Spectropoint Pin Tool for high throughput spotting of 
samples onto the chip for reading, and software to design SNP assays. The software 
designs multiplex reactions genotyping up to 12 SNPs per well. The procedure followed 
is detailed below. 
2.4.3 Assay Design 
The goal of designing multiplex reactions is to maximize the potential of the 
Sequenom mass array system while preventing reactions within the SNP primers being 
tested. The software lumps assays based on termination mix and tests for primer overlap 
to prevent cross reaction within and between primers to ensure that the only amplification 
is of target DNA. There are three different primers designed for each SNP, forward and 
reverse PCR primers for amplification of a DNA fragment containing the SNP, and a 
massEXTEND primer that is used to determine which allele is present at the SNP site. 
The massEXTEND primers are designed to have a melting temperature of 60°C or 
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greater, which is accomplished with GC content. GC pairs require more energy to break 
than AT pairs because they contain three hydrogen bonds versus two. To be able to 
distinguish between multiple reactions the massEXTEND primer mass cannot be 
identical to any other primer in the multiplex mixture. Termination mix is the 
replacement of three of the four nucleotides from deoxynucleotides to dideoxynucleotides 
which cannot be extended and thus terminate the strand. The correct termination mix is 
determined by the software which ensures that the extensions do not go beyond three 
bases before terminating. 
2.4.4 Polymerase Chain Reaction 
Template DNA was extracted from case and control samples and diluted to 2.5 
ng/J.tl concentration for use in PCR. Primers were 20-30 nucleotides in length, contained 
approximately 40-60% G or C nucleotides to induce stable binding of primers without 
forming secondary structure which would impair binding. A PCR master mix was created 
containing forward and reverse primers, buffer, 1.5M magnesium chloride, deoxynucleic 
acids (dATP, dCTP, dGTP, dTTP), and Taq DNA polymerase, 4J.tL of master mix was 
placed in each sample well, to which lJ!L of2.5ng/J!L DNA was added. Standard PCR 
cycling programs for multiplex reactions were used (95°C for fifteen minutes, 45 cycles 
of [95 °C for twenty seconds, 56 °C for thirty seconds, 72 °C for one minute], 72 °C for 
three minutes, 4 °C). 
2.4.5 SAP Treatment 
Two microlitres of a SAP master mix containing sterilized deionized water, 
homogeneous mass extend buffer and SAP were added to each sample well using the 
multimek robot pipettor. The reaction including the SAP mixture was incubated in the 
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PCR machine according to standard protocol (37 °C for twenty minutes, 85 °C for five 
minutes, 4 °C). 
2.4.6 Homogenous massEXTEND Reaction 
The massEXTEND reaction is an amplification of the polymorphism site in the 
fragment using PCR. The massEXTEND primers were added to hME buffer and an 
aliquot of 2J!L was added to each sample well by multimek robot pipettor. The PCR 
reaction times differed if the reaction was multiplexed, assessing several SNPs (94 °C for 
two minutes, 100 cycles of [94 °C for five seconds, 52 °C for five seconds, 72 °C for five 
seconds], 4 °C forever); or uniplexed, assessing a single SNP (94 °C for two minutes, 45 
cycles of [94 °C for five seconds, 52 °C for five seconds, 72 °C for five seconds], 4 °C). 
2.4. 7 Spectr6clean Resin Treatment 
Upon completion of the extension reaction, the samples were treated with 
Spectroclean resin to remove any cations that would interfere with the mass array signal. 
The resin was mixed with the sample and distilled water using the multimek robot and 
then centrifuged at high speeds to prevent the resin from being transferred to the reading 
surface of the chip. A mass array silicon dioxide chip was spotted with the samples from 
a 384 well plate by the MassARRA Y nanodispenser. The chip was then transferred to the 
reading plate of the Bruker Biflex mass spectrometer and sealed. The spotted chip was 
then read by the mass array under vacuum using a laser to aerosolize the sample and 
interpret the mass reading into spectra. These spectra were converted into genotype calls 
for each SNP based on expected masses of allele fragments by the software of the 
equipment. 
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2.4.8 Analysis of the VNTR of IL-lRA 
The IL-lRa repeat allele was analyzed using PCR, restriction enzymes and gel 
electrophoresis. 
PCR 
The variable number tandem repeat (VNTR) of IL-lRA was amplified by PCR 
using the a standardized cycling protocol (94 °C for two minutes, 40 cycles of [94 °C for 
one minute, 58 °C for one minute, 72 °C for one minute], 72 °C for two minutes, 4 °C ). 
The PCR products were run on a 1% agarose gel. Bands were visualized with ethidium 
bromide treatment and the size of the VNTR fragment was determined using a molecular 
weight ladder. 
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Chapter 3 Results 
3.1 Demographics 
Demographics of the case and control groups are shown in Table 1. The case 
group consisted of 101 patients, with mean age of 45.6 years (standard deviation 12.4), 
mean age of onset at 25 years (11.8). Seventy percent of the case group was male, and 
88% of the patients were HLA-B27 positive, which is consistent with standard AS 
demographics. The control group consisted of 103 volunteers from the community, with 
mean age of 44 (13.7), and 39% of this group was male. 
Eighty seven percent of our AS patients had girdle joint involvement, specifically 
the hip. Assessment was made of extra-articular involvement in the case group from data 
obtained in the questionnaire. Achilles tendonitis caused by enthesitis was seen in 38.4% 
of our patients. Table 2 shows the status of our AS population with respect to extra-
articular involvement of disease. Common comorbidities of AS include IBD, iritis, and 
psoriasis. With respect to IBD in our population, 9.1% of patients were diagnosed with 
ulcerative colitis, and 4.04% had a diagnosis ofCrohn's disease. Iritis was a common 
extra-articular involvement in our population, with 44.4% of the cases experiencing at 
least one occurrence. Psoriasis was also present in 20.2% of the case population. 
3.2 Hardy Weinberg 
The control group met Hardy Weinberg equilibrium for all the SNPs examined in 
which minor alleles were present in the Newfoundland population. The data for controls 
was entered into a spreadsheet calculation using actual allele frequencies of homozygotes 
to calculate a theoretical frequency of heterozygotes. This was then multiplied by the 
sample size to yield a theoretical number of heterozygotes in the population. 
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Table 1: Demographic information for case and control groups 
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Cases Controls 
N 101 103 
Percent male 70% 39% 
Mean age 45.6 44 
(years) ±12.4 ± 13.7 
Mean age of 25 N/A 
onset (years) ± 11.8 
HLA-B27 88% -
Status 
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Table 2: Comorbidity status in ankylosing spondylitis patients examining 
extent of extra-articular involvement in the patient cohort. 
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Comorbidity Percentage of 
AS Patients 
(%) 
Ulcerative 9.1 
Colitis 
Crohn's Disease 4.04 
Iritis 44.4 
Psoriasis 20.2 
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This theoretical value was then compared to the actual observed number of heterozygotes 
using chi-square analysis to determine if any difference was statistically significant. As 
differences between theoretical and observed allele frequencies in the control group was 
not statistically significant at p=0.05, it can be said that Hardy-Weinberg equilibrium was 
maintained in the population for these alleles, and any difference between case and 
control groups is not due to inherent differences in the population. 
3.3 Primary Outcome 
With respect to association of gene allele to disease susceptibility, several 
important results were noted summarized in Table 3. Values marked with a* were 
provided by Dr. Rahman by personal communication from ongoing research, and values 
marked with tare statistically significant with a=0.05. On preliminary analysis with chi-
square statistics, SNPs from the TNFa, CARD15, and TLR4 genes appeared to be 
significantly associated with disease status, and SNPs from TGF-~ and ALX4 showed 
trends towards significance. From further analysis of the allele frequencies using logistic 
regression, the only SNPs that retained statistical significance when corrected for 
multiple analysis are the SNPs at positions -308, and -863/-1031 in linkage 
disequilibrium of the TNFa promoter region and the Asp299Gly polymorphism ofTLR4. 
Further analysis ofthe TLR4 haplotype with Haploview software (done by a statistician 
for publication of results) revealed an association of the minor allele haplotype with 
disease (p=0.03) (Snelgrove et al., submitted). The TNFa SNPs were less prevalent in 
cases than in controls, while the TLR4 variants were more prevalent in the case 
population. It is also of note that the minor alleles for the SNPs chosen for FGFR2, 
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Table 3: Allele Frequencies and associated P values of SNPs located within 12 
candidate genes in ankylosing spondylitis patients and controls from 
the Newfoundland population. 
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Gene SNP N Case N Control A p p 
Case _(%) Control (_o/C!l_ (%) value cor'd 
TNF-a 238 (A) 100 4.5 103 5.33* -0.8 0.8197 0.567 
308 (A) 100 10.0 103 18.9* -8.9 0.0114 o.oo8r 
857 (T) 100 11.0 103 7.7* +3.3 0.3079 0.338 
863 (A) 100 5.5 103 12.9* -7.4 0.0002 o.ooor 
1031 (C) 100 5.0 103 22.8* -17.8 <0.0001 (LD) 
IL-l IL-Ia (T) 100 33.0 95 31.0* +2.0 0.381 
Cluster IL-lf3 (T) 100 24.5 95 25.3* -1.1 0.477 
IL-lRa (2) 75 34.0 86 25.6* +8.4 0.1118 
IL-10 IL-10 (A) 100 51.0 86 48.8* +2.2 0.378 
CARD15 702 (T) 101 0.0 90 3.9* -3.9 0.0048 o.oo2r 
908 (C) 100 0.5 90 2.8* -2.3 0.1054 0.170 
1007 (C) 101 2.5 89 0.56* +1.9 0.2207 0.187 
TLR4 299 (G) 100 7.5 98 2.55 +4.95 0.0366 o.o5r 
399 (T) 101 7.4 100 3.0 +4.4 0.0707 0.09 
TGF-p 1800471 (C) 98 8.7 100 6.5 +2.2 0.4518 0.430 
1800468 (A) 101 8.9 100 11.5 -2.6 0.4142 0.456 
1800469 (T) 99 30.3 99 36.9 -6.6 0.2016 0.216 
ALX4 3802805 {T) 101 34.6 100 27.0 +7.6 0.1058 0.265 
3824915 (G) 93 33.9 97 25.8 +8.1 0.0928 0.108 
FGFR2 3135824 (C/T) 100 0 100 0 
3135827 (CIT) 100 0 100 0 
3135829 (CIT) 100 0 100 0 
1047102 (A/G) 100 0 100 0 
4647921 (CIT) 100 0 100 0 
4647922 (A/G)) 100 0 100 0 
TCIRGl 7479081 (CIT) 100 0 100 0 
1047817 (C/T) 100 0 100 0 
2471829 (C/G) 100 0 100 0 
DLL3 7249157 (CIT) 100 0 100 0 
5828039 (-/C) 100 0 100 0 
t p<0.05 
*personal communication, P. Rahman 
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TCIRGl, and DLL3 were not present in the Newfoundland population in either cases or 
controls. 
3.4 Secondary Outcomes 
The TNFa and TLR4 polymorphisms were examined for association with 
secondary outcomes using logistic regression. No association was found between 
polymorphism and gender, age of disease onset, BASDAI score greater than 4, or BASFI 
score greater than 5 which are standard cutoffs of disease severity. 
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Chapter 4 Discussion 
4.1 The benefit of studying the genetic associations of disease susceptibility 
AS has a large genetic burden and its sibling recurrence risk is among the highest 
for any complex disease. Thus, examining the genetic basis of disease is useful as 
identifying genes involved in susceptibility may allow for elucidation of disease 
mechanisms that are otherwise difficult to understand. Genetic variants can be used to 
identify risk early in life allowing for better management and fewer delays in diagnosis 
for individuals expressing symptoms. Further analysis of the functional consequences of 
these variants can be potentially used to develop treatment targets for biologic agents that 
will halt progression of the disease or become therapeutic options to reduce 
symptomatology. 
There are large regions associated with AS susceptibility and a systematic 
analysis of these areas is necessary to determine the true susceptibility genes. Examining 
genes within the regions that have been linked to AS by genome wide scan is important 
even if the results show these candidates are not linked to AS. Since the areas are large 
there are multiple genes that have potential involvement in susceptibility and reducing the 
number of genes that must be examined will allow narrowing of the susceptibility 
regions. As long as the study has the power to detect a significant association, negative 
results will further narrow the regions of interest. 
4.2 Challenges in genetic association study design 
One of the challenges in identifying genes with small to moderate impact on 
genetic susceptibility is the inherent heterogeneity in phenotype and genotype for 
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complex diseases. To minimize phenotypic heterogeneity, the modified New York 
criteria standardized method of diagnosis for AS was used as a strict guideline for 
inclusion in the study. Genetic heterogeneity in complex disease refers to the contribution 
of multiple genes to susceptibility and subsequent development of disease. Different 
combinations of genotypes may lead to the same disease phenotype. Using the founder 
population ofNewfoundland minimizes the genotypic heterogeneity of the study 
population. Reducing these heterogeneities will further enhance the signal of genes 
contributing small to moderate risk for AS susceptibility. 
Linkage disequilibrium is both a challenge and a benefit of using a founder 
population. Genetically homogenous populations such as founder populations and 
isolates have larger areas of linkage disequilibrium due to the natural expansion of the 
population. Large areas of linkage disequilibrium allow for positive associations for 
polymorphisms distant from the true susceptibility allele but linked evolutionarily. The 
challenge with linkage disequilibrium is further research is required to determine whether 
the polymorphism examined is the one conferring risk for the disease or whether it is just 
linked to an allele that confers risk. The next step in the research instigated by this study 
is to further analyze regions identifies as warranting closer examination using high 
marker density methods. 
Another challenge in complex disease genetic research is incomplete penetrance. 
As many genes are likely to be involved in risk and susceptibility with a threshold of 
alleles necessary for disease development, it is possible that individuals in the "control" 
population will carry some of risk alleles without developing AS. This frequency of 
alleles in the control population will reduce the differences between cases and controls, 
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potentially minimizing the true significance of the alleles. The bias this would add to our 
study is to mimize the true association, with more likelihood of a false negative than a 
false positive. With AS, however, the low prevalence of disease makes it unlikely that 
there are susceptibility alleles in the control population. This risk can also be minimized 
by controlling the age of the control group. The mean age in this study was over 40, thus, 
it is highly unlikely there are any people in the control population that have AS and are 
not yet into the symptomatic disease course. 
Environmental factors are also known to play a role in developing AS. As 
populations can differ with respect to environmental exposure, this fact could impact the 
genetic research of AS. Theoretically it is possible that members of the control group 
have the genetic susceptibility factors required to develop AS but have not developed 
symptoms because they have not been exposed to the environmental trigger. The impact 
of environmental factors on this study is that it is possible the frequencies of candidate 
genes in the control population does not accurately reflect frequencies in individuals who 
are not at risk for developing AS and have been exposed to the environmental trigger. 
While using a founder population in an environment such as Newfoundland will 
minimize this problem as exposure rates for most microbes are equal throughout the 
province, since the microbial trigger of AS is unknown it is impossible to say whether the 
control and case groups were equally exposed to the environmental factors responsible 
for AS development. 
Population stratification is a challenge in genetic research. Population 
stratification refers to the potential confounder of genetic factors related to ethnicity on 
the study. Population stratification is a concern in large heterogeneous populations with 
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multiple lines of ancestry. Using the founder population of Newfoundland reduces the 
potential error due to population stratification as the population is relatively 
homogeneous when compared to other study populations. Using unrelated controls from 
the same population further reduces the magnitude of this confounding factor. 
Potential sources of bias were minimized as much as possible. All interviewers 
were trained in measurement taking and assessments as a group prior to the first patient. 
This reduces the interobserver bias. The patient performed the parts of the questionnaire 
that are subjective responses themselves, with the interviewer explaining the scale but not 
asking the questions. This reduced any expectation bias on the part of the patient. 
4.3 Genetic Epidemiology 
This field of research is rapidly evolving and until recently study design was quite 
variable and false positive results were commonly reported due to poorer quality studies. 
A recent publication of guidelines for genetic association studies will allow more uniform 
investigations and data interpretation from several population studies will be easier in 
meta-analysis (Freimer, 2005). As this study was completed prior to the publication of 
these guidelines, not all objectives listed were achieved. Objectives met by this study 
include the following. Each candidate chosen for this study was discussed separately as to 
the reasons for interest in AS, either from previous research, which was cited, or due to 
what is known about the function of the gene. When discussing candidates for this study, 
an effort was made to identify the populations in which the prior studies were performed, 
as population differences may account for differences in results. P-values were corrected 
for multiple testing within each gene examined. Objectives that were not achieved by this 
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study were reporting of p values obtained by previous studies, as differences in 
population prevalence of alleles makes comparison difficult, probability statistics were 
not utilized to determine whether the list of candidate genes was likely to produce a 
relevant result, and the significant p value was set at 0.05 not 10-7• Were this study to be 
repeated, the suggested guidelines would be integrated into the study design as well as 
expanding the sample size to remove any issues of power limitations. 
4.4 Candidate gene selection 
The tumor necrosis factor a gene was chosen based on position within the MHC 
region of chromosome 6. Several previous studies examining two of the SNPs chosen for 
this study have given different results for different populations (as reviewed in 
introduction). Three of the SNPs examined have not yet been tested in AS patients. The 
controversy coupled with the marked effectiveness of the anti-TNFa agents in AS 
patients make this gene an interesting candidate for this study. 
The cytokines interleukin 1, interleukin 1 0 and tumor growth factor ~ (IL-l, IL-
l 0, TGF~) were chosen based on position within areas of interest identified on genome 
wide scan (reviewed in Sims et al., 2004). These cytokines were also chosen due to 
association with other inflammatory arthropathies or extra-articular manifestations seen 
in AS, as reviewed in the introduction. 
The genes for caspase recruitment domain-containing protein 15 and toll-like 
receptor 4 (CARD15, TLR4) were chosen based on their location in the chromosome as 
well as their function as signaling molecules involved in the innate immune response to 
intestinal flora. The CARD 15 gene has recently been associated with psoriatic arthritis in 
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the Newfoundland population (Rahman et al., 2003b ). The TLR4 gene has recently been 
studied in the Dutch population, as discussed in the introduction. 
The genes for fibroblast growth factor receptor 2, aristaless-like homeobox 4, 
delta-like three, and T-cell immune regulator 1 (FGFR2, ALX4, DLL3, TCIRGl) were 
all chosen based on their proximity to regions previously associated with AS (reviewed in 
Sims et al., 2004) and based on function ofthe gene product. All four of these genes 
appear to play some role in bone metabolism regulation as mutations lead to diseases 
involving bone pathology, as discussed in detail in the introduction. 
4.5 Interpretation of Results in this study 
4.5.1 Gene Discovery 
The toll like receptor 4 (TLR4) gene is within the region on chromosome 9q that 
was identified as a susceptibility region (reviewed in Sims et al., 2004). TLR4 is a 
signaling molecule that initiates a response against lipopolysaccharide via stimulation of 
NF-KB which induces transcription of pro-inflammatory cytokines such as TNFa. 
Lipopolysaccharide is a major component of Gram negative cell walls. TLR4 also 
recognizes lipoteichoic acid, endogenous heat shock protein 60 ligands (HSP60), 
fibronectin, and hyaluronic acid (van der Paardt et al., 2005). The Asp299Gly 
polymorphism has been shown to reduce this response. The importance of this reduction 
in vivo is still being elucidated. The TLR4 gene is of interest based on both position and 
function. While the microbial trigger of AS is unknown, it is likely that a decreased 
response to this pathogen would allow it to remain in the system for longer periods of 
time before clearance by the immune system and allow it to trigger onset of the disease. 
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Thus, signaling molecules such as TLR4 are important considerations in understanding 
how the genotype influences the phenotype and the mechanism of AS susceptibility. 
This study noted an increase in prevalence of the minor allele in the case 
population (p=0.05). The implications of this result involves minor allele functional 
misregulation of the innate immune system conferring susceptibility to AS. This result 
could help further elucidate the mechanism of AS onset and the connection between 
environmental triggers and disease. 
Despite a previous negative association study between AS and TLR4, this study 
found a positive result with both SNP (see Table 3) and haplotype analysis (using 
Haploview). This may be in part due to the differences in populations used, and again 
points to the benefits of using a young founder population such as the one in 
Newfoundland, and it is possible the result of this study is a false positive. False positive 
results are possible through chance, multiple testing or linkage disequilibrium. The 
effects of chance were minimized by holding a significant alpha of 0.05 but still are a risk 
inherent to any statistical technique. Multiple testing was minimized by correcting the p 
value and using logistic regression for the secondary outcomes. 
The next step in the analysis of TLR4 and AS is independent validation in other 
populations, haplotypes involving more markers, and further functional analysis of the 
polymorphisms studied. This study proposes that this further investigation is warranted. 
The association of this gene to disease could provide a further biological target for 
pharmaceuticals to control disease development and progression. 
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4.5.2 Gene validation 
Cytokines are very important in initiating and maintaining the inflammatory 
response. TNFa. is a very potent cytokine with many effector cells. Regulation ofTNFa. 
production is thus important to normal function. Control of1NFa production occurs at 
both the transcriptional and posttranscriptionallevels (Wilson et a/., 1997). The promoter 
region ofTNFa is key to control at the transcriptional level. There are recognition 
sequences for several transcription factors in the 1NFa. promoter, as well as recognition 
sites for synthesis inhibitors such as the anti-inflammatory cytokines (Liz-Grana eta/., 
2001). DNase I footprinting has shown the -308 polymorphic site as a hypersensitive site 
for cleavage with a protected area adjacent (Wilson et a/., 1997). The region containing 
the -1031 and -863 polymorphisms is involved in induction of expression by MKK6(EE) 
and MLK3 (Hoffmeyer eta/., 1999). 1NFa. has the strongest biological relevance to AS. 
Strong evidence for a role ofTNFa. in AS are the effectiveness of the biologic agents. 
The findings of this study (see Table 3) have been validated in other populations 
(Stone eta/., in press). The polymorphisms at positions -308, and -863/-1031 in linkage 
disequilibrium were negatively associated with diseases susceptibility, meaning the 
presence of the minor alleles may have a protective role in AS onset. The promoter 
polymorphisms may be in linkage disequilibrium with the true functional polymorphism, 
or they may themselves have functional consequences by interfering with 1NFa. 
regulation at the transcriptional level. Since it appears that the -1031 and -863 
polymorphisms are in linkage disequilibrium the former explanation seems likely. 
Linkage disequilibrium is a challenge, while it does help identify areas of interest in the 
Newfoundland population, it is difficult to ascertain whether the SNP analyzed is 
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associated with the disease or just linked to the true susceptibility polymorphism. The 
true susceptibility polymorphism is elucidated by higher density gene mapping and 
examining the area for the highest association to susceptibility which would be a future 
direction of this study. 
Further study of these polymorphisms in populations of AS patients being treated 
with the biologic medications could identify genetic prognosticators of success or failure. 
The capability to investigate the pharmacogenetics ofTNFa and the biologic agents in 
the Newfoundland population is limited due to the fact that the number of AS patients is 
small, and the number of these patients on biologic therapy is quite small. These 
polymorphisms can also be examined in larger centers for prognostic factors of severity 
and outcome. While no association with current BASDAI and BASFI was found in this 
study, the sample size may be too small to detect a difference, and as this was a case 
control study, the data is taken at one point in time, while a cohort design may be a better 
way to answer the question of prognostic associations. 
4.5.3 Lack of Disease Association 
False negatives are a potential problem of any genetic association study. There are 
several ways in which a falsely negative result can occur. Power of the study to capture 
the difference between groups is an important factor. It is possible some of the small 
differences noted are significant but our sample size is not sufficient to be captured 
statistically. It is also likely that some of the susceptibility genes are population specific, 
which would correlate with different disease prevalence by population, as is seen with the 
CARD15 alleles in the Japanese population. This study was also not designed to 
accurately capture interactions with environmental and other gene polymorphisms with 
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the genes being studied. Thus it is possible that a combination of factors is necessary for 
disease development which may not have been met in the control population who carried 
the polymorphisms studied. An example is lack of exposure to a pathogenic trigger 
organism. While it is likely that these results are not false negatives, it is prudent to 
examine larger studies from other populations before fully disregarding these candidates. 
Most of the SNPs examined were not statistically significantly associated with 
disease. The SNPs that had no minor alleles present in the Newfoundland population 
were those for the genes FGFR2, TCIRGl, and DLL3 (Table 3). These findings are 
important for future research in this population as these SNPs were not present in either 
case or control groups and thus are unlikely to be found in the Newfoundland population 
as a whole. These genes have not been examined with respect to AS before and this 
preliminary research suggests that further research involving the regions from which 
these genes originate is warranted. The examination of other genes involved in bone 
disease is necessary to elucidate the mechanism of ankylosis in AS. 
The negative results in this study, both the genes with no minor alleles present in 
the population, and other candidates chosen (IL-l, IL-10, ALX4, TGF-~, and CARD IS) 
also show that logical and positional correlation with disease does not translate into 
genetic association. Searching for genes associated with complex diseases is a 
complicated process. 
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4.6 Limitations of Study 
4.6.1 Sample size-power issues 
Genetic studies are limited by the populations used. The Newfoundland 
population used in this study adds power to the study, as the reduction in the signal to 
noise ratio provided by the Newfoundland population will make any modest gene 
contributions more readily detectable. However, by limiting the studies to a specific 
population, we limit the potential sample size of the study. This is a case control study of 
a disease with a prevalence of only 1-3 out of 1000 in Caucasian populations (Bown et 
al., 2003). As the Newfoundland island population was estimated by Canadian census to 
be 482,000 in 2001, the maximum sample size is 482 patients with a 100% participation 
rate. A further complication to sample size is the issue of independent samples. This 
disease has a strong genetic component for susceptibility. This genetic component results 
in multiple affected family members. These samples are not independent as there may be 
genetic factors other than the ones being studied contributing to risk. This removal of 
affected family members decreases the available sample pool from which to draw 
samples. As a result, one goal of this study was to obtain as many independent samples as 
possible from the population being studied, which for this study was just over 100 
unrelated cases. 
4.6.2 Newfoundland population 
Using the Newfoundland population gives an enhanced signal to noise ratio 
allowing detection of genes with small to moderate effects on risk. This is a benefit of a 
founder population. A limitation of this population is the relative homogeneity of the 
population prevents generalization to an admixed population. As a result genes identified 
65 
using this population must be validated in larger populations with mixed heritage to truly 
assign risk. The advantage of using this population is that it can identify genes that 
warrant extended research in these admixed populations that would not be identified 
using similar techniques in the heterogeneous population. The results of this study will be 
used to stimulate further study of the polymorphisms with marginal significance in the 
Toronto population as a continuation of the work initiated with this thesis. 
4.6.3 Demographic differences between groups 
While the difference in gender between the two groups is statistically significant 
(p<0.05), none of the genes examined are related to the X chromosome or have 
expressions influenced by sex hormones. It has also been reported that AS is not 
associated with the X chromosome. However, this difference in group composition, 
stemming from the nature of the volunteer control population and the higher prevalence 
of AS in males, was noted. 
4.6.4 Absence of replication studies 
Another limitation of this study is that the polymorphisms found to be 
significantly associated with AS in the Newfoundland population are not supported by 
the current literature. While there is some evidence that TNFa is associated with AS, 
there are as many negative studies as positive ones published and the polymorphisms 
found to be significant vary from population to population. Some of these discrepancies 
may be explained by population differences, and that the use of the founder population 
enables smaller associations to be readily seen. 
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Chapter 5 Conclusions 
5.1 Outcomes 
The TNFa and TLR4 genes seem to be associated with Ankylosing Spondylitis in 
the Newfoundland population. The TNFa promoter polymorphism minor alleles were 
statistically less prevalent in cases than controls. A novel association was noted in this 
study. The TLR4 Asp299Gly polymorphism was significantly more prevalent in cases 
than controls. These polymorphisms were not associated with gender, age of onset, or 
measures of severity, the BASDAI and BASFI. 
5.2 Clinical significance of results 
While the polymorphisms found were statistically associated with the disease, 
their use in screening is not warranted. The presence of the TNFa promoter 
polymorphism minor alleles seem to be protective for the disease, but are still present in 
the disease population so the presence of the polymorphism cannot be used to rule out a 
diagnosis of Ankylosing Spondylitis. The TLR4 polymorphism is a risk factor for the 
disease, but the polymorphism is present in the control population as well so it cannot be 
used to definitively diagnose AS and will have poor predictive value as a diagnostic test 
for AS. 
5.3 Importance of population 
This study illustrates the importance of the study population on interpretation of 
the results of genetic testing. While using a founder population has its advantages, mainly 
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with detection of genes that would normally be lost in the noise of genetic heterogeneity, 
the limitation with any genetic study remains that the results are generalizable only to the 
population being studied. This reduced generalizability is seen with all populations, and 
thus it is important when conducting literature reviews to note the population being 
studied. 
The founder population of Newfoundland allows for great strides to be made in 
hypothesis generating investigations by indicating candidate genes that warrant 
hypothesis testing, Hypothesis testing involves a higher marker density and haplotype 
analysis, which is costly and time consuming. By doing hypothesis generating studies of 
single nucleotide polymorphisms that are likely to have functional consequences in a 
population where the linkage disequilibrium and the signal to noise ratio is high, the 
genes that make it to the second stage of research have been shown to likely be involved 
in disease pathogenesis and susceptibility. This allows for more efficient and focused 
research. 
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October 2003 
Faculty of Medicine, Schools of Nursing and Pharm~cy of Memo :rial 
University of Newfoundland; Health Care Corporation, St. John's; Newfoundland Cancer 
Treatment and Research Foundation 
Consent to Take Part in Health Research 
TITLE: Genetic Linkage Study of Al1kylosing Spondylitis 
INVESTIGATOR(S): Drs. P. Rahman, R. Inman, M. Stone 
SPONSOR: National Institutes ofHealth 
You have been asked to take part in a research study. It is up to you to decide whether to be 
in the study or not. Before you decide, you need to understand what the study is for, ¥?hat 
risks you might take and what benefits you might receive. This consent form explains the 
study. 
The researchers will: 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
Ifym.1 decide not to take part or to leave the study this will not affect your normal treatment 
1. Introduction!Backg:round: 
Anlcy1osing Spondylitis is a disease that has genetic risk factors. These risk factors have yet to be 
identified. Finding these risk factors will lead to a faster diagnosis of disease and earlier treatment 
in patients. Tllis early diagnosis and treatment may help slow the development of the disease. 
2. Purpose of study: 
The purpose of this study is to identify inherited and environmental factors that affect the immune 
system leading to the development of Ankylosing Spondylitis. This study may eventually lead to a 
better m1derstanding and treatment of this disease. 
3. Description of the study procedures and tests: 
You will be asked to: 
1. allow the researchers to review your medical records and x-rays 
2. complete a questimmaire about your medical and family history 
3. have a genetic blood test (2 tubes of blood approximately 10 mls) 
Aug 30,2004 -1- Initials: __ _ 
4. Length of time:. 
You will be asked to complete a questiom1aire during one visit taking about L! 5 minutes 
5. Possible risks and discomforts: 
There is a risk of slight pain or bruising when your blood is drawn. 
6. Benefits: 
It is not lmown whether this study will benefit you. 
7. Statement on Genetic studies 
In order to interpret the results of the research properly, it is essential to have accurate information 
concerning parentage. Sometimes the research results may point out discrepancies in parentage 
(which may occur in case of adoption or a mistake in the identity of a father). If this happens, the 
infonnation will be kept in the strictest confidence and will not be released to anyone, including 
family members and yourself. 
8. Future use of DNA 
In order to preserve a valuable resource, your DNA samples may be stored at the end of this 
research project. It is possible that these samples may be useful in a future research project v-.rhich 
may or may not be related to the cun-ent research project. Any future research would have to be 
approved by a Research Ethics Board (REB). 
Please tick one of the following three options: 
0 1. I agree that my DNA samples can be used for any REB-approved research project 
(about inflammatory diseases), including those in which my name is given to the 
researchers, without obtaining further consent from me. 
0 2. Specific consent must be obtained from me before using my DNA samples in any 
future research project in which my name is associated with the sample. 
0 3. Under no circumstances may my DNA samples be used for any future research 
project. The samples must be destroyed at the end of the present project. 
Signature -------------- Date: _____ _ 
Witness: 
----------------
Date: _____ _ 
9. Liability statement: 
Signing this form gives us your consent to be in this study. It tells us that you understand the 
information about the research study. When you sign this form, you do not give up your legal 
rights. Researchers or agencies involved in this :research study still have their legal and 
professional responsibilities. 
Aug 30,2004 
-2- Initials: __ _ 
10. Questions: 
:U you have any questions about taking part in this study, you can meet with the 
investigator who is in charge of the study at this institution. That person is: 
Dr Proton Rahmal'. 777-5733 
Or you can talk to someone who is not involved with the study at an, but can advise you 
on your rights as a participant in a research study. This person can be reached through: 
Aug 30,2004 
Office of the Human Investigation Committee CHIC) at 709-777-6974 
Email: hic@mun.ca 
-3- Initials: 
---
Signature Page 
Study title: Genetic Link:age study of Ankylosing Spondylitis 
Name of principal investigator: Dr. Proton Rahman 
To be filled out and signed by the participant: 
Please check as appropriate: 
I have read the consent [and information sheet]. 
I have had the opportunity to ask questions/to discuss this study. 
I have received satisfactory answers to all of my questions. 
I have received enough information about the study. 
I have spoken to a physician and my questions have been answered 
I tmderstand that I am free to withdraw from the study 
• at any time 
• without having to give a reason 
e without affecting my future care 
I understand that it is my choice to be in the study and that I may not benefit. 
I agree that the study doctor or investigator may read the parts of my hospital 
records which are relevant to the study. 
I agree to take pa."'i in this study. 
Signature of participant Date 
Signature ofwitness Date 
To be signed bv the person obtaining consent: 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
I have explained this study to the best of my ability. I invited questions and gave answers. I believe 
that the participant fully understands what is involved in being in the study, any potential risks of 
the study and that he or she has freely chosen to be in the study. 
Signature of person obtaining consent Date 
Telephone number: (709)777-5733 
Aug30, 2004 
-4- Initials: __ _ 
Ankylosing Spondylitis Questionnaire 
DATE OF ASSESSMENT (Y/M/D) ----- FAMILY# _____ _ 
NAME _________________________________ __ PID __ _ 
MAIDEN NAME--------------------- REFERRED BY ___ _ 
ADDRESS ________________________ _ 
Tel. (H)---------(W) _______ ~~--
-------------'----- PreferCall: l.Day 2.Evening 
RELATIONSHIP TO PROBAND l.Proband 2.Parent 3.Sibling 4.Child 5.0ther ___ _ 
DOB (Y/M!D) ___ _.MCP ___________ GENDER l.Male 2.Female 
FATHER'S PID 
FATHER'S RELIGION _______ _ 
ETHNICITY 
1. Caucasian 
2. Other Specify _____ _ 
MARITAL STATUS 
MOTHER'S PID 
MOTHER'S RELIGION _____ _ 
You 
Mother 
Father 
Maternal GF 
Maternal GM 
Paternal GF 
Paternal GM 
l.Single 2.Married 3.Widowed 4.Divorced 5.Separated 6.Common Law 
EDUCATION 
l.<grade 8 2.Grade 8 3 .Highschool grad 4. College 
EMPLOYMENT STATUS 
1. Employed 
5. Disabled 
2. Retired 
6. Sick Leave 
3. Homemaker 
7. Looking for Work 
5. University 
4. Student 
8. Other 
CRF collected by the patient 
Patient initials 
Date of completion (d/m/y) 
Centre 
Rheumatologist initials 
NRS pain 
Please tick the box that represents your answer ( i.e.~ 
36. Nocturnal Back Pain 
uuu 
UU UU JUU 
uu 
uuu 
Based on your assessment, please indicate what is the amount of back pain at night that 
you experienced during the last week? 
no pain most severe pain 
37. Total Back Pain 
Based on your assessment, please indicate what is the amount of back pain at any time 
that you experienced during the last week? 
no pain most severe pain 
NRS patient global disease activity 
38. Please tick a box to indicate your overall assessment of your disease activity during the 
last week. 
none severe 
NRS BAS-G 
39. Please tick a box to indicate the effect your disease has had on your well-being over the last 
week. 
none very severe 
40. Please indicate the effect your disease has had on your well-being over the last six 
months. 
none very severe 
NRS BASDAI 
Patient initials 
Date of completion (d/m/y) 
Centre 
Rheumatologist initials 
Please tick the box which represents !);J answer. 
All questions refer to last week. (i.e. ) 
uuu 
UU UU JLJU 
uu 
uuu 
41. How would you describe the overall level of fatigue/tiredness you have experienced? 
none very severe 
42. How would you describe the overall level of AS neck, back or hip pain you have had? 
none very severe 
43. How would you describe the overall level of pain/swelling in joints other than neck, back or 
hips you have had? 
none very severe 
44. How would you describe the overall level of discomfort you have had from any areas tender 
to touch or pressure? 
none very severe 
45. How would you describe the overall level of morning stiffness you have had from the time 
you wake up? 
none 
46. How long does your morning stiffness last from the time you wake up? 
0 
hr 
1 
hr 
very severe 
2 or more 
hrs 
I Patient initials uuu 
NRS BASFI 
Please indicate your level of ability with each of the following activities during the last week. 
(i.e. ~) 
(An aid is a piece of equipment which helps you to perform an action or movement) 
· 47. Putting on your socks or tights without help or aids (e.g. sock aid). 
easy impossible 
48. Bending forward from the waist to pick up a pen from the floor without an aid. 
easy impossible 
49. Reaching up to a high shelf without help or aids (e.g. helping hand). 
easy impossible 
50. Getting up out of an armless dining room chair without using your hands or any other help. 
easy impossible 
51. Getting up off the floor without help from lying on your back. 
easy impossible 
52. Standing unsupported for 1 0 minutes without discomfort. 
easy impossible 
J Patient initials uuu 
53. Climbing 12-15 steps without using a handrail or walking aid. One foot at each step. 
[0]--[JJ--[U--GJ 
easy impossible 
54. Looking over your shoulder without turning your body. 
easy impossible 
55. Doing physically demanding activities (e.g. physiotherapy exercises, gardening or sports). 
easy impossible 
56. Doing a full days activities, whether it be at home or at work. 
easy impossible 
I Patient initials uuu 
ASQol 
Below you will find some statements which have been made by people who have Ankylosing 
Spondylitis. 
Please read each statement carefully. We would like you to tick "yes" if you feel the statement 
applies to you, and tick "no" if it does not. 
Tick the one response that applies best to you at the moment. 
57. My condition limits the places I can go yes 
-
no 
58. I sometimes feel like crying yes 
-
no 
59. I have difficulty dressing yes 
-
no 
60. I struggle to do jobs around the house yes 
-
no 
61. It's impossible to sleep yes 
-
no 
62. I am unable to join in activities with my friends/family yes 
-
no 
63. I am tired all the time yes 
-
no 
64. I have to keep stopping what I am doing to rest yes 
-
no 
65. I have unbearable pain yes 
-
no 
66. It takes a long time to get going in the morning yes 
-
no 
67. I am unable to do jobs around the house yes 
-
no 
-68. I get tired easily yes 
-
no 
69. I often get frustrated yes 
-
no 
70. The pain is always there yes 
-
no 
71. I feel I miss out on a lot yes 
-
no 
72. I find it difficult to wash my hair yes 
-
no 
73. My condition gets me down yes 
-
no 
7 4. I worry about letting people down yes 
-no 
SYMPTOMS SHADE CIRCLES FOR ALL THAT APPLY 
Yes No 
INFLAMMATORY BOWEL 
Ulcerative Colitis 0 0 
Crohn's Disease 0 0 
Uveitis/Iritis 0 0 
Psoriasis 0 0 
Reiter's Syndrome 0 0 
Or Reactive Arthritis 
Peripheral Arthritis 0 0 
Hips, Shoulders 
Peripheral Arthritis 0 0 
Other 
JOINT REPLACEMENT 
Hip Replacement 
Knee Replacement 
Other Replacement 
OTHER 
Sausage Digits 
Heel Pain 
( enthesitis) 
FUNCTIONAL CLASS 
GRADE 1: 
GRADE2: 
GRADE3: 
GRADE4: 
0 0 
0 0 
0 0 
0 0 
0 0 
1 2 3 4 
All activities without pain or handicap 
Adequate for most ADL but some discomfort or limitation 
ADL limited to self-care and/or few daily activities 
Little or no self-care or confined to a bed or wheelchair 
Date Dx 
(y/m/d) 
X-RAY FINDINGS ------------------------
MEDICATIONS (CIRCLE ALL THAT APPL 1') 
NSAIDS DMARDS 
ASA-enteric coated never past present Gold-IM never. past present 
Phenylbutazone never past present Imuran never past present 
Idomethacin (Indocid) never past present S ulphasalazine never past present 
Ibuprofen (Motrin) never past present Cyclosporin never past present 
Naproxen (Naprosyn) never past present Oral Steroids never past present 
Tolmetin (Tolectin) never past present Chloroquine never past present 
Ketoprofen ( Oruidis) never past present Hydroxycloroquine never past present 
Surgam never past present MTX-oral never past present 
Diclofenac (Voltaren) never past present MTX-irnlsc never past present 
Feldene never past present Fish Oil never past present 
Other (specify) never past present Retinoid never past present 
Other never past present 
PHYSICAL EXAMINATION 
Height em Weight kg BP I Pulse 
Head and Neck Lungs 
Abnormal N y Abnormal N y 
Conjunctivitis N y COLD N y 
Iritis N y other (specify) N y 
Uveitis N y 
M. membrane ulcers N y 
Heart Abdomen 
Abnormal N y Abnormal N y 
Arrythmia N y Hepatomegaly N y 
Heart failure N y Splenomegaly N y 
Valvular disease N y 
Lymphadenopathy Skin 
Cervical N y Psoriasis N y 
Axillary N y Flexural psoriasis N y 
Inguinal N y Guttate N y 
Multiple N y Erythroderma N y 
Nail lesions N y 
CNS Pits N y 
Abnormal N y Onycholysis N y 
Cranial neuropathy N y Ridges N y 
Peripheral neuropathy N y 
Other (specify) N y Muscle 
Proximal Weakness N y 
Distal Weakness N y 
HLA-B27 l.Yes 2.No 3.Don'tKnow Date (y/m/d) 
Result !.Positive 2. Negative 
SURGERY FOR ARTHRITIS I. Yes 2.No Type 
OTHER SURGERY Date (y/mld) Type 
Date (y/rnld) Type 
Date (y/rnld) Type 
AFFECTED l.Yes 2.No 
DNA COLLECTED 1. Yes (y/rnld) 2.No 
INTERVIEWED BY: _____________ (Y/M/D) ______ _ 
ISSAS 
Patient initials 
Date of completion (d/m/y) 
Centre 
Rheumatologist initials 
CRF collected for every patient by the metrologist 
1. Country 
uuu 
UU LJU JUU 
uu 
uuu 
NL 
Belgium 
Germany 
France 
Italy 
Spain 
Finland 
Norway 
UK 
us 
Canada 
-
-
-
-
-
-
-
-
-
-
_, 
2. Date of birth (day/month/year) 
3. Gender 
4. Year of symptom onset 
5. Year of diagnosis 
6. Radiographic sacroiliitis 
7. History of peripheral arthritis 
8. History of lBO 
9. Hip involvement 
10. Total hip replacement 
11. Paid job 
12. Current sick leave 
Total SwoUen 
Joint 1ndex 
(44 Joints) 
unilateral 
unilateral 
Mexico 
-Australia 
UU !UU !UU 
male 
-female 
uuuu 
uuuu 
bilateral no unknown 
yes no 
ves no 
ves no 
bilateral no 
ves no 
yes no 
13. Number of swollen joints: count and mark the swollen joints on the mannequin U U 
21 March 2003 
I 
I 
Number of tender enthesis 
These are the sites marked on the manne uin: 
C11C2 
C7/T1 
Costochondral 1 rille 
Costochondral 7 rille 
T121L 1 
L5/S1 
Crista iliaca ri lie 
Anterior Superior border of iliac crest rille 
Symphysis pubis 
Patient initials 
Date of completion (dimly) 
Centre 
Rheumatologist initials 
uuu 
UU LJU JUU 
uu 
uuu 
Pelvic adductor origin rille 
Ischial tuberosities ·rille 
Greater Trochanter rille 
Spina iliaca posterior rille 
Spina iliaca anterior superior rille 
Medial femurcondyl rille 
Lateral femurcondyl rifle 
Insertion Achilles tendon rille 
Plantar fascia rille 
The patients' response to firm palpation over these entheses. 
uu 14. Number of tender enthesis 
21 March 2003 
I Patient initials 
15. Occiput wall distance 
(Heels and, if possible, the back against the wall, with the distance 
measuredin centimeters to the nearest 0. 1 em from the occiput to the wall 
during maximal effort to touch the head to the wall, without raising the chin 
above its usually carrying level. The best of two tries should be recorded) 
16. Modified Schober test 
(This test is performed by marking a point over the spinous process of L5 
(found as the first process below the projected line across the back at the 
level of the top of the iliac crest, although the exact point is not absolutely 
critical). The second point directly 10 em above the first, while the patient is 
extending his lumbar spine in neutral position. The patient then flexes 
forward as far as possible and the distance between· the two points is 
measured. Normally the 10 em distance increases to 16 em or more. The 
difference should be written (in this case 10116, while 10110 would indicate 
no change on flexion of the lumbar spine). The actual distance in 
centimeters measured in full flexion should be recorded, rather than the 
difference between the extension and the flexion of measurements) 
17. Lateral spinal flexion 
(Is measured by fingertip to floor distance in full lateral flexion without 
flexing forward or bending the knees. The patient should stand as close to 
the wall as possible with shoulders /eve/. The distance between patient's 
middle fingertip and the floor is measured with a tape measure. The patient 
is asked to bend sideways without bending his knees or lifting his heels 
and attempting to keep his shoulders in the same place. A second reading 
is taken and the difference between the two is recorded. The best of two 
tries is recorded for left and right. The mean of left and right gives the final 
result for lateral spinal flexion (in em to the nearest 0. 1 em) 
18. Chest expansion 
(The difference in centimeters to the nearest 0. 1 em between full expiration 
and full inspiration, measured at the nipples. The best of two tries should 
be recorded) 
19. Cervical rotation 
(Is measured with a gravity action goniometer. The patient lies supine in 
the neutral position and the goniometer is placed centrally on the forehead. 
The patient is then asked to turn the head as far as possible to the right 
and then to the left. The best of two tries for left and right should be 
recorded. The mean of left and right gives the final result in degrees) 
20. lntermalleolar distance 
(The patient supine, the knees straight and the feet pointing straight up. 
The patient is asked to separate the legs as far as possible and the 
distance between the medial malleoli is measured (in em to the nearest 
em). The best of two tries should be recorded) 
uuu 
UU,Uem 
UU,U em 
UU W em 
UU U em 
' 
uu u 0 
UU U em 
I Patient initials uuu 
2'1. ESR (within last 3 months) value uuu! 
22. ESR increased (according to own lab) yes no n.a. 
23. CRP (within last 3 months) value uu 
24. CRP increased (according to own lab) yes no n.a. 
25. Activity on MRI (only if available) yes no n.a. 
26. Rapid radiographic progression (only if available) yes no n.a. 
27. Activity on scintigraphy (only if available) yes no n.a. 
28. Activity on ultrasonography (only if available) yes no n.a. 
29. Current treatment for AS Indomethacin 
-Diclofenac 
-Eterecoxib 
-Ibuprofen 
-Naproxen 
-Piroxicam 
-Nebumetone 
-Meloxicam 
-Rofecoxib 
-Celecoxib 
-Other 
30. Daily dose of this medication (mgram) uuuu 
31. Number of previous treatments for AS with NSAIDs other than the present NSAID 0 
-
1 
-2 
-
>2 
32. Maximal dose of these NSAIDS used yes 
-
no 
33. Reason for discontinuation inefficacy 
-intolerance 
-both 
34. Current treatment with sulfasalazine 
-
methotrexate 
-biphosphonates 
-
thalidomide 
-TNF-blocker 
-
systemic corticosteroids 
-injections with corticosteroids 
-other 
35. Previous treatment with sulfasalazine 
-
methotrexate 
-biphosphonates 
-thalidomide 
-TNF-blocker 
-
systemic corticosteroids 
-injections with corticosteroids 
-other 
A. 
B. 
c. 
Patient initials 
Date of completion (d/m/y) 
Centre 
Rheumatologist initials 
uuu 
UU tUU UU 
uu 
uuu 
ISS AS 
CRF collected for every patient by the rheumatologist 
Do you want to start therapy with TNF-blockers in this patient under the folowing assumptions: 
1. the treatment gives an improvement of at least 50% in at least 50% of the patients; 
2. the drugs are available and fully reimbursed; 
3. there may be an increased risk for (serious) infections and little information is available on long 
term safety. 
This judgemen+ should be made independent of the patient's wish to start TNF-blockers. 
-yes 
no 
The dominant localisation of symptoms is: 
axial 
-peripheral arthritis 
enthesitis 
This decision is based on: (tick all those that are applicable) 
clinical disease activity 
disease severity (including structural damage on radiographs, loss of spinal mobility, 
-loss of physical function etc.) 
rapid functional decline (in the previous 0-2 years) 
hip involvement 
peripheral arthritis 
other extras pinal manifestations 
rapid radiographic progression (in the previous 2-4 years) 
disease activity on MRI 
increased ESR or CRP 
disease inappropriately controlled with present treatment 
recurrent infections 
past history of tuberculosis 
co-morbidity 
high risk of adverse events in this patient 
expected low compliance in this patient 
other reasons, please specify ................................................................................. 
························································································································ 
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Ankylosing Spondylitis Family Study 
DNA Banking for Newfoundland Families 
Dr. R. Inman 
Toronto Western Hospital 
Fell Pavilion 1-221 
399 Bathurst St. 
Toronto, ON 
M5T2S8 
Telephone: (416) 603-5869 
Date Blood Collected 
Personal Identifying Number 
Relation to Proband 
Gender 
Clinical Diagnosis 1. 
Dr. Proton Rahmani Donna Hefferton 
1st Floor Morrissey Wing 
St. Clare's Mercy Hospital 
LeMarchant Rd. 
St. John's, NF 
A1C5B8 
Telephone (709) 777-5733 
Email : dheffert@morgan.ucs.mun.ca 
0 Proband. 0 Sibling 0 Parent 0 Child 
0 Other (specify) _______ _ 
0 Male 0 Female 
0 Ankylosing Spondylitis 
2. 0 Unaffected 
FUTURE USE OF DNA AUTHORIZED BY PARTICIPANT: 
0 Any REB-Approved research project including those in which participant's name is used. 
0 Need participant's consent for studies in which participant's name is associated with the 
sample. 
O'Not to be used for any future project, destroy samples at the end of the present project. 
~. ....._ .. 
3 sodium-heparinized tubes -
2 EDTA tubes 
Ank)Tiosing Spondylitis Familv Study 
DNA Banking for Newfoundland Families 
Dr.R.Inman 
Toronto Western Hospital 
Fell Pavilion 1-221 
399 Bathurst St. 
Toronto, ON 
M5T2S8 
Telephone: (416) 603-5869 
Date Blood Collected 
Personal Identifying Number 
Relation to Proband 
Gender 
Clinical Diagnosis 1. 
Dr. Proton Rahman/ Donna Hefferton 
1st Floor Morrissey Wing 
St. Clare's Mercy Hospital 
LeMarchant Rd. 
St. John's, NF 
AlC5B8 
Telephone (709) 777-5733 
Email : dheffert@morgan.ucs.mun.ca 
0 Proband 0 Sibling 0 Parent 0 Child 
0 Other (specify) ---------
0 Male 0 Female 
0 Ankylosing Spondylitis 
2. 0 Unaffected 
FUTURE USE OF DNA AUTHORIZED BY PARTICIPANT: 
0 Any REB-Approved research project including those in which participant's name is used. 
0 Need participant's consent for studies in which participant's name is associated with the 
sample. 
0 Not to be used for any future project, destroy samples at the end of the present project. 
3 sodium heparinized tubes 
- 2 'EDT A tubes 
October 2003 
F acuity of l-.iedicine, Schools of Nursing and Pharmacy ofJviemorial 
University of Newfoundland; Health Care Corporation, St. John's; Newfoundland Cancer 
Treatment and Research Foundation 
Consent to Take Part in Health Research 
TITLE: Genetic Linkage Study of Anl.,:ylosing Spondylitis 
INVESTIGATOR(S): Drs. P. Ralunan, R. Ilm1an, M. Stone 
SPONSOR: Nationalil1stitutes ofHealth 
You have been asked to take part in a research study. It is up to you to decide whether to be 
in the study or not. Before you decide, you need to understand what the study is for, what 
risks you. might take and what benefits you might receive. This consent form eA.'])lains the 
study. 
The researchers will: 
• discuss the study with you 
e answer your questions 
• keep confidential ~my information which could identify you personally 
• be available during the study to deal with problems and answer questions 
If you decide not to take part or to leave the study this will not affect you.r normal treatment 
1. I:nt:roduction/Background: 
.Ankylosing Spondylitis is a disease that has genetic risk factors. These risk factors have yet to be 
identified. Finding these risk factors will lead to a faster diagnosis of disease and earlier treat.1TI.ent 
in patients. This early diagnosis and treatment may help slow the development ofthe disease. 
2. Purpose of study: 
The purpose of this study is to identify inherited and environmental factors that affect the inunune 
system leading to the development of Ankylosing Spondylitis. This study may eventually lead to a 
better understanding and treatment of this disease. 
3. Description ofthe study procedures and tests: 
You will be asked to: 
1. allow the researchers to review your medical records and x-rays 
2. complete a questimmaire about your medical and family history 
3. have a genetic blood test (2 tubes ofblood approximately 10 mls) 
Aug 30.2004 -1- Initials: __ _ 
4. Length of time: 
You will be asked to complete a questiom1aire during one visit -.:aking abou~ 45 minutes 
5. Possible risks and discomforts: 
There is a risk of slight pain or bruising when your blood is drawn. 
6. Benefits: 
It is not lmown whether this study will benefit you. 
7. Statement on Genetic studies 
In order to interpret the results of the research properly, it is essential to have accurate infom1ation 
conceming parentage. Sometimes the research results may point out discrepancies in parentage 
(which may occur in case of adoption or a mistake in the identity of a father). If this happens, the 
infonnation will be kept in the strictest confidence and will not be released to anyone, including 
family members and yourself. 
8. Future use of DNA 
In order to preserve a valuable resource, your DNA samples may be stored at the end oftbis 
research project. It is possible that these samples may be useful in a future research project which 
may or may not be related to the cu..1Tent research project. Any future research would have to be 
approved by a Research Ethics Board (REB). 
Please tick one of the following three options: 
0 1. I agree that my DNA samples can be used for any REB-approved research project 
(about inflammatory diseases), including those in which my name is given to the 
researchers, without obtaining further consent from me. 
0 2. Specific consent must be obtained from me before using my DNA samples in any 
future research project in which my name is associated with the sample. 
0 3. Under no circumstances may my DNA samples be used for any future research 
project. The samples must be destroyed at the end of the present project. 
Signature ----------------------------- Date: ______ _ 
Witness: 
------------------------------
Date:, ______ _ 
9. Liability statement: 
Signing this form gives us your consent to be in this study. It tells us that you understand the 
information about the research study. VVhen you sign this form, you do not give up your legal 
rights. Researchers or agencies involved in this research study still have their legal and 
professional responsibilities. 
Aug 30,2004 -2- Initials: ___ _ 
10. Questions: 
If you. have any questions about taking part in this study, you can meet with the 
investigator who is in charge of the study at this institution. That person is: 
Dr Proton Rahman 777-5733 
Or you. can talk to someone who is not involved with the study at all, but can advise you 
on your rights as a participant in a research study. This person can be reached through: 
Aug 30,2004 
Office of the Human Investigation Committee (HI C) at 709-777-6974 
Email: hicl@.mun.ca 
-3- Initials: 
---
Signature Page 
Study title: Genetic Linkage study of Ankylosing Spondylitis 
N arne of principal investigator: Dr. Proton Rahman 
To be filled out and signed by the participant: 
Please check as appropriate: 
I have read the consent [and information sheet]. 
I have had the opportunity to ask questions/to discuss this study. 
I have received satisfactory answers to all of my questions. 
l have received enough infonnation about the study. 
I have spoken to a physician and my questions have been answered 
I understand that I am free to withdraw from the study 
• at any time 
• without having to give a reason 
• without affecting my future care 
I understand that it is my choice to be in the study and that I may not benefit. 
I agree that the study doctor or investigator may read the parts of my hospital 
records which are relevant to the study. 
I agree to take pa.'i in this study. 
Signature of participant Date 
Signature ofwitness Date 
To be si!!ned bv the person obtaining consent: 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No {} 
Yes {} No { } 
Yes {} No {} 
Yes {} No {} 
I have explained this study to the best of my ability. I invited questions and gave answers. I believe 
that the participant fully understands what is involved in being in the study, any potential1isks of 
the study and that he or she has freely chosen to be in the study. 
Signature of person obtaining consent Date 
Telephone number: (709)777-5733 
Aug30, 2004 -4- Initials: ________ ____ 
